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Stellingen behorende bij het proefschrift 
''Factors i1ifluencing outcome in acute ischaemic stroke 
Outcome scales, the role ef blood glucose and rtP A treatment" 
1. De Barthel Index is een minder geschikt instrument om patienten met een herseninfarct 
nauwkeuriger te graderen op de gemodificeerde Rankin schaal. (dit proefschrift) 
2. Hyperglykemie is geassocieerd met een slechte uitkomst bij corticale herseninfarcten maar juist 
niet bij lacunaire herseninfarcten. (dit proefschrift) 
3. De veiligheid van intraveneuze trombolyse als behandeling voor het acute herseninfarct tussen 
de 3 en 4,5 uur na het ontstaan van de symptomen is vergelijkbaar met intraveneuze 
trombolyse binnen 3 uur na het ontstaan. (dit proefschrift) 
4. Patienten van 80 jaar of ouder hebben een grotere kans op een slechte uitkomst, maar geen 
hoger risico op een hersenbloeding na intraveneuze trombolyse, ten opzichte patienten jonger 
dan 80 jaar. (dit proefschrift) 
5. Trombocytenaggregatieremmers voorafgaand aan intraveneuze trombolyse verhogen de kans 
op een hersenbloeding, maar zijn daarentegen geassocieerd met een betere functionele 
uitkomst. (dit proefschrift) 
6. Een TIA (Transient Ischaemic Attack) kan beschouwd warden als een TIB (Threatening 
Infarct of the Brain) en vereist daarom urgente diagnostiek en behandeling. (Stroke 2004; 35:e13 
& Lancet 2007; 370:143242) 
7. Een wetenschappelijk pas send antwoord op het gezegde "you need a brain to get a migraine 
(H.C. Diener)" is "het brein kent geen (hoofd)pijn (B.M. de Jong, september 2001'/' 
8. Het zou op korte termijn mogelijk gemaakt moeten warden om neurologen en neurochirurgen 
op te leiden in het uitvoeren van neuroradiologische interventies. 
9. Een van de meest moeilijke differentiaal diagnoses is die van je eigen huilende baby. 
10. "A neat desk is a sign of a sick mind." 
11. Woorden zijn ook <laden. (L11d1vig Wittgenstein 1953) 
12. Er zijn maar weinig borden zo ineffectief als die van het rookverbod voor de hoofdingang van 
hetUMCG. 
13. Veel problemen kunnen warden opgelost door er geen probleem van te maken. 
14. Niet alles wat gemeten kan warden is waardevol en niet alles wat waardevol is kan gemeten 
warden. (Albert Einstein) 
15. Wie nog nooit van mening is veranderd, heeft zelden iets geleerd. 
Maarten Uyttenboogaart 
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The management of acute ischaemic stroke has undergone a dramatic 
change since the introduction of stroke care units and intravenous 
thrombolysis with recombinant tissue plasminogen activator (rtPA). The 
two main concepts in the treatment of acute ischaemic stroke are 
neuroprotection and early reperfusion. The rationale behind the stroke 
care unit is based on the concept of neuroprotection. Admittance to a 
stroke care unit has been shown to improve survival and clinical 
outcome.1'2 Early reperfusion therapy with intravenous rtP A has 
nowadays become a standard treatment in a selected group of ischaemic 
stroke patients and as a consequence acute ischaemic stroke is 
considered to be a medical emergency. 
Despite these new developments, the burden of ischaemic stroke 
remains high. In the Netherlands, the annual number of ischaemic stroke 
patients is estimated to be 30,000 and ischaemic stroke is responsible for 
about 25% of all cardiovascular deaths.3 Although the worldwide 
incidence of ischaemic stroke has declined in the last years due to 
primary and secondary prevention, the absolute number of patients is 
still increasing because of the ageing population.4•5 
Aetiology of ischaemic stroke 
The aetiology of ischaemic stroke can be divided into large vessel 
atherosclerosis, cardioembolic stroke, small vessel disease and unknown 
or other rarer causes.6 Large artery atherosclerosis is the most common 
cause and leads to stenosis or occlusion of extra or intracranial arteries. 
Due to endothelial damage and narrowing of the blood vessel lumen, the 
coagulation cascade is stimulated and thrombi may develop. Large artery 
atherosclerosis is often associated with vascular risk factors such as 
hypertension, hypercholesterolaemia, smoking, diabetes mellitus, and 
hyperhomocysteinaemia.7-9 In the case of cardioembolic stroke, emboli 
originate from the heart, most frequently due to arrhythmias, valve 
diseases, myocardial disorders or septal lesions.10 Small vessel disease can 
lead to single or multiple lacunar infarctions 11 due to microatheromatosis 
or lipohyalinosis.12 Lacunar syndromes are usually caused by small end­
artery infarctions and are characterised by neurological deficits without 
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the presence of 'cortical signs', such as aphasia, apraxia, hemianopia, 
neglect or gaze palsy.13 The most important risk factors for cerebral 
small vessel disease are hypertension and diabetes mellitus. 8 Other causes 
of ischaemic stroke ( eg arterial dissections or coagulation disorders) are 
much less common, especially in the elderly. For adequate treatment and 
prognostic purposes, it is important to determine the cause of stroke and 
to determine the clinical stroke subtype.13 
Pathophysiology of acute ischaemic stroke 
During acute ischaemia, the reduction of cerebral blood flow in the 
occluded or stenosed artery results in impaired glucose and oxygen 
supply to the adjacent brain tissue. Subsequently, lactate is produced due 
to anaerobic glycolysis, to keep up the synthesis of Adenosine 
Triphosphate (ATP), which is necessary for cell metabolism. Excessive 
lactate production impairs the function of the Na+ /Ca2+ pump, which 
results into a massive influx of calcium. 14 Excessive release of glutamate 
activates N-methyl-D-aspartate (NMDA) and cx-amino-3-hydroxyl-5-
methyl-isoxazole propionate (AMP A) receptors results in an increase of 
intracellular calcium. This elevated intracellular calcium concentration 
activates catabolic enzymes that destroy cell membranes and nucleic 
acids, and leads to the formation of free radicals, finally resulting into 
neuronal cell death. 14 For a long time, the ischaemic cascade was 
considered to be an irreversible process, which would inevitably lead to 
cell death. Later, Astrup et al, described the concept of the ischaemic 
penumbra and showed that the ischaemic cascade is a dynamic process, 15 
and that the speed of this cascade highly depends on the residual cerebral 
blood flow in the affected brain tissue. 
The penumbra is a zone where neurons have lost their function, 
leading to neurological deficit. However, these neurons may be rescued 
and survive if blood flow is restored. In prolonged depression of blood 
flow, damage will be irreversible and cells in the penumbra will convert 
to the infarct core. Normally the cerebral blood flow is above 50 
ml/100g/min. A flow between 20-50 mg/100g/min reflects a zone of 
oligaemia. 16'17 The threshold for the cerebral blood flow at which 
3 
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neurons do not function anymore is believed to be around 20 
ml/lO0g/min.17 The region with a cerebral blood flow below 8-10 
ml/100g/min is considered to reflect the infarct core (figure 1).17 
Imaging studies have demonstrated that the penumbra can be visualised 
with positron emission tomography (PET),18'19 perfusion/ diffusion 
weighted magnetic resonance imaging (MRI)20-22 and perfusion computed 
tomography (CT) scans.23 
Figure 1: During cerebral ischaemia, three different zones can be identified 
There are several factors that influence the viability of the 
penumbra. Disturbance of vital parameters, such as blood pressure, 
arterial oxygen saturation and body temperature during acute stroke may 
accelerate the development of irreversible neuronal damage.1 Monitoring 
these parameters and correcting disturbances in homeostasis in stroke 
units, improves clinical outcome and reduces mortality rates.2 
Another important factor that is believed to negatively influence the 
penumbra is a high blood glucose level. Several studies have 
demonstrated that admission hyperglycaemia during acute stroke is 
associated with a worse outcome. 24-28 Suggested pathophysiological 
mechanisms are local tissue acidosis caused by increased lactate 
production in anaerobic glycolysis, excess of glutamate production and 
damaging of the endothelial cells and the blood brain barrier. 29-31 
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Hyperglycaemia is associated with worse outcome,32 especially in the case 
of successful reperfusion after thrombolysis. It has also been associated 
with intracerebral haemorrhage following rtP A treatment, possibly by 
damaging the blood brain barrier. 33 Trials investigating the effects of 
lowering blood glucose on clinical outcome in stroke patients with 
hyperglycaemia are underway. The relation between hyperglycaemia and 
outcome among different ischaemic stroke subtypes is not well known. 
Animal experiments have suggested a different effect of hyperglycaemia 
in end-artery infarctions compared to large cortical infarctions. 34 
Measuring outcome after acute ischaemic stroke 
In the previous years, many trials on the effectiveness of neuroprotective 
drugs in acute stroke have been performed. However, results were 
disappointing in a sense that none of the tested neuroprotective drugs 
positively influenced the outcome, even though previous animal 
experiments had shown most promising results. One of the reasons for 
these negative results may be the use of inadequate outcome 
measures. 35'36 
To determine whether acute stroke therapies are efficacious, a 
precise definition of outcome measures is important. Most previous 
stroke trials used degree of disability, mortality or stroke severity as 
outcome measures. Commonly used outcome instruments for measuring 
disability are the modified Rankin scale (mRS) and Barthel Index (BI). 
The Rankin scale was originally designed as a handicap scale,37 but was 
later modified38 and, as such, the mRS is considered to be a disability 
scale rather than a handicap scale. 39 The mRS is divided into six disability 
grades and one grade for death ( see Appendix 1). The BI is an activities 
of daily living (ADL) scale and measures the degree of disability on the 
10 different items (see Appendix 2).40 The cumulative score ranges from 
0 (completely disabled) - 100 (no disability at all). In previous stroke 
trials, both the mRS and BI have often been dichotomised dividing 
patients into good or poor outcome.41 There is, however, no consensus 
on how to define outcome with these scales and there are many 
discrepancies among the chosen cut-off scores in previous stroke trials.41 
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It is also unclear how the BI and mRS are related to each other: some 
trials only used one of the scales, whereas others used both the mRS and 
BI to measure efficacy of treatment.42'43 
Thrombolysis for acute ischaemic stroke 
Currently the most important established reperfusion therapy for acute 
ischaemic stroke is intravenous thrombolysis with recombinant tissue 
plasminogen activator (rtPA).44 The rationale behind rtPA treatment is 
that a thrombus responsible for the vascular occlusion is dissolved by 
fibrinolysis. If the cerebral blood flow is restored in time, neurons in the 
ischaemic penumbra may be rescued. The equilibrium between 
thrombus formation and fibrinolysis depends on the interplay between 
plasminogen activators and inhibitors.45'46 The endogenous process of 
fibrinolysis is enhanced by plasminogen activator through the conversion 
of plasminogen into plasmin. Plasminogen activator inhibitors reduce the 
activity of plasminogen activator (figure 2).47 Plasmin can break down 
fibrin and fibrinogen. Exogenous plasminogen activator also accelerates 
the conversion of plasminogen to plasmin and may induce dissolution of 
the thrombus with subsequent reperfusion (figure 3). Besides 
degradation of fibrin, plasmin can also degrade proteins in the basal 
lamina from the blood vessels which may lead to intracerebral 
haemorrhage (ICH). As a consequence, the most feared complication of 
thrombolytic therapy in stroke is the development of ICH (figure 4). 
Besides haemorrhagic complications, it has been suggested that tissue­













Figure 2: Regulation of ftbrino/ysis 
Different types of plasminogen activators have been investigated in 
clinical trials. Intravenous treatment with either streptokinase or 
urokinase did not show any beneficial effect.49-51 Intra-arterial (IA) 
administration of urokinase has been tested in two randomised 
controlled trials: the Prolyse in Acute Cerebral Thromboembolism 
(PROAC1) I and II. 52'53 In these trials higher recanalisation rates and a 
better clinical outcome were observed in the group who received IA 
urokinase and heparin compared to heparin treatment only, despite a 
higher incidence of ICH. 
Three large randomised controlled trials on rtP A have been 
performed. The National Institute of Neurological Disorders Stroke 
(NINDS) study showed a beneficial effect of rtP A on clinical outcome in 







Figure 3: Angiograpf?y of a patients with a proximal right M 1  occlusion (arrow) of 
the middle cerebral artery (left), with succesiful recanalisation cifter intra-arterial 
thrombo!Jsis (right). (Used with permission from the American Medical Assodation 
(Copyright© JAMA 1999, 282(2 1), 2003- 1 1, All rights reserved)). 
Figure 4: Brain CT scan of patient who received rtP A treatment. Left CT is before 
treatment showing subtle ear!J ischaemic changes in the right hemisphere. Right CT, 
approximate!J 6 hours cifter rtP A treatment, showing a large parencf?ymal 
haematoma. 
A higher incidence of symptomatic ICH was observed in rtPA 
treated patients compared to placebo. The number needed to treat was 
estimated to be six, meaning one excellent recovery for every six treated 
patients. The European Cooperative Acute Stroke Study (ECASS)-I used 
a dose of 1.1 mg/kg and a time window of 6 hours from stroke onset. 42 
Although results for the primary endpoint were negative, a subgroup 
analysis excluding the patients with major protocol violations revealed a 
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favourable effect of rtP A. The incidence of parenchymal haematoma was 
higher in the rtP A group than in the placebogroup. In the ECASS-II the 
same dose as in the NINDS trial was used and treatment was started 
within 6 hours. 55 Again no statistical significant difference in the primary 
outcome (mRS :S 1) was observed, although a post-hoc analysis using a 
cut-off score of mRS :S 2 demonstrated a beneficial effect of rtP A. The 
Alteplase ThromboLysis for Acute N oninterventional Therapy in 
Ischaemic Stroke (ATLANTIS) found no significant rtP A benefit when 
treatment was initiated between 3 to 5 hours of stroke onset. 56 A 
systematic review of thrombolytic therapy demonstrated that rtP A 
reduced the proportion of patients dead or dependent, but increased the 
risk of ICH.51 A pooled analysis of the three large rtPA trials illustrated 
that the effectiveness of rtP A gradually decreases with longer onset to 
treatment times, but also suggested a beneficial effect of rtP A up to 4.5 
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Figure 5: Estimated odds ratio 's far favourable outcome at  3 months (rtP A 
compared to placebo). Favourable outcome was defined as global endpoint ef mRS 
score :S 1) NIHS S score :S 1 and BI score 2:: 9 5. OIT = onset to treatment time. 
(Used with permission from Elsevier, The Lancet, 2004) 3 6 3 (94 1 1  )) 7 68-7 4 ). 
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Recently, the Safe Implementation of Thrombolysis in Stroke 
Monitoring Study (SITS-MOST), a large multicenter study, showed that 
rtPA treatment was safe and feasible in clinical practice.58 
Despite the evidence from these studies that rtP A is efficacious and 
feasible, only a small proportion of stroke patients receive this treatment. 
In most centres the percentage patients receiving rtP A varies from 
roughly 1 % to 10%.59-70 There are several reasons for this low 
percentage: the most frequently reported cause is that stroke patients do 
not arrive at the hospital within 3 hours after stroke onset. 61•62•67-69 Other 
reported causes are exclusion of mild or rapidly improving stroke 
62 67 k · "th k 67 ld 69 · "fi  symptoms, ' awa erung w1 stro e symptoms, o er age, s1gru 1cant 
comorbidity,61 or presence of any other absolute or relative exclusion 
criteria.65 Little is known, however, about which subgroups of patients 
are likely to benefit from rtP A treatment and which patients are at risk 
for haemorrhagic complications or a poor outcome. A closer 
investigation of prognostic factors could contribute to a larger number 
of patients who will benefit from rtP A treatment. 
Objectives and outline of the thesis 
The three main objectives of this thesis are to investigate: 1) the relation 
between the BI and mRS, and their role in measuring outcome in acute 
ischaemic stroke, 2) the role of hyperglycaemia in acute ischaemic stroke 
and 3) safety aspects and prognostic variables in acute ischaemic stroke 
patients who received rtP A treatment. 
Chapters 2 and 3 describe the relation between the BI and mRS, 
using data of two previous stroke trials. In Chapter 2 we searched for 
the optimal cut-off scores on both BI and mRS, which can be used for 
future stroke trials as consistent and uniform endpoints. Chapter 3 
assesses the relation between the BI and mRS in more detail by 
comparing the total scores and item scores on the BI in each mRS grade. 
The accuracy of the assigned mRS grades was also assessed based on the 
item scores on the BI. Based on the results of these chapters, we decided 
to choose the mRS as outcome measure in further studies, using a 
structured interview ( see Appendix 4). 71 
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In Chapter 4, the relation between elevated blood glucose levels 
during acute ischaemia and functional outcome is assessed in lacunar and 
non-lacunar strokes. 
Chapters 5 - 9 deal with safety aspects and prognostic factors in 
acute ischaemic stroke patients treated with rtPA at the University 
Medical Center Groningen. In a prospective patient registry, we recorded 
data from consecutive patients treated with intravenous rtP A. 
As previously mentioned, many stroke patients do not arrive at the 
hospital within 3 hours of stroke onset. In Chapter 5 we studied the 
feasibility of rtP A treatment between 3-4.5 hours in daily practice, as a 
favourable effect of rtP A was observed in a pooled analysis of trial 
data. 57 The outcomes of patients treated between 3 and 4.5 hours of 
stroke onset were compared with those treated within 3 hours. 
In most rtP A trials patients older than 80 years were excluded from 
treatment. In Chapter 6, the outcomes of thrombolytic therapy in 
patients aged 80 years or older were investigated and compared with the 
outcomes in their younger counterparts. In this chapter, we selected only 
patients treated within 3 hours and defined favourable outcome as mRS 
0-1, to make our results comparable with those of previous studies 
regarding rtP A treatment in octogenarians. 
In Chapter 7, we studied the safety of rtPA treatment in patients 
using antiplatelet drugs. A substantial number of stroke patients have a 
history of previous vascular events and use antiplatelets at stroke onset. 
Little is known about the relation between prior antiplatelet therapy and 
risk of symptomatic ICH. On the other hand, cardiologists usually 
administer antiplatelets in addition to thrombolytic therapy to prevent 
reocclusion,72 which might also be the case during cerebral thrombolysis. 
In previous studies, low cholesterol levels were found to be 
associated with an increased risk of primary intracerebral haemorrhage. 73-
76 In Chapter 8, the possible influence of admission cholesterol and 
triglyceride levels on the risk of symptomatic ICH and on clinical 
outcome was investigated. In addition, we examined whether statin use 
was associated with symptomatic ICH or clinical outcome. 
Recently, a predictive model has been developed to assist clinical 
decision making in balancing the risks and benefits of rt-PA.77 This so 
called stroke thrombolytic predictive instrument ( s-TPI) uses a number 
1 1  
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of clinical characteristics to predict the probability of a good (with or 
without rtP A) outcome or very poor outcome in individual patients. In 
Chapter 9, we examined the external validity of the s-TPI in daily 
clinical practice. 
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Abstract 
Introduction - There is little agreement on how to assess outcome in 
acute stroke trials. Cut-off scores for the Barthel Index (BI) and 
Modified Rankin Scale (mRS) are frequently arbitrarily chosen to 
dichotomise favourable and unfavourable outcome. We investigated 
sensitivity and specificity of BI cut-off scores in relation to the mRS, to 
obtain the optimal corresponding BI and mRS scores. 
Methods - BI and mRS scores were collected from 1034 ischaemic 
stroke patients. Sensitivity and specificity were calculated for BI cut-off 
scores from 45 to 100 in mRS score 1, 2 and 3 and were plotted in 
receiver operator characteristic (ROC) curves. 
Results - The cut-off scores for the BI with the highest sum of 
sensitivity and specificity were 95 (sensitivity: 85.6%, specificity: 91.7%), 
90 (sensitivity: 90.7%, specificity: 88.1 %) and 75 (sensitivity: 95.7%, 
specificity: 88.5%) for respectively mRS 1, 2 and 3. The area under the 
ROC curve was 0.933 in mRS 1, 0.960 in mRS 2 and in 0.979 in mRS 3. 
Conclusions - The optimal cut-off scores for the BI were 95 for mRS 
1 ,  90 for mRS 2 and 75 for mRS 3. For future acute stroke trials that 
assess stroke outcome with the BI and mRS, we recommend the use of 
these BI cut-off score(s) with the corresponding mRS cut-off score(s), to 
ensure the use of consistent and uniform endpoints. 
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Introduction 
Several randomised controlled acute stroke trials have been designed to 
investigate effectiveness of therapeutic interventions. A major point of 
discussion is how to define outcome in acute stroke trials with disability 
and handicap scales.1 -6 The most widely used scales are the modified 
Rankin Scale (mRS) and the Barthel Index (BI). 
The mRS has proved to be valid and reliable for defining outcome in 
stroke patientsY Although the mRS was designed as a handicap scale,9 it 
should be considered as a disability scale.10 The mRS defines 6 different 
grades of disability, from 0 'No symptoms at all' to 5 'Severe disability; 
bedridden, incontinent and requiring constant nursing care and attention' 
and grade 6 for death (see Appendix 1). 
The BI has also shown to be valid and reliable for assessing disability 
in stroke patients. 8'1 1  It contains 1 0  items with varying weights that score 
activities of daily living (ADL). The items bathing and grooming are 
scored 0 or 5. The items feeding, dressing, controlling bladder, 
controlling bowel, getting onto and off the toilet, ascending and 
descending stairs, are scored 0, 5 or 10. Items regarding moving from 
wheelchair to bed and walking on level surface are scored 0, 5, 10 or 15. 
The total BI is a cumulative score of the 10 items with a maximum score 
of 100, corresponding with complete independence and a minimum 
score of 0, corresponding with total dependence (see Appendix 2). 
There is little consensus on the optimal implementation of the BI 
and mRS as outcome-measure in acute stroke trials. It is unclear which 
outcome scale is preferable. Moreover, the cut-off scores distinguishing 
favourable and unfavourable outcome are highly variable between 
various acute stroke trials.4 This issue has great consequences for the 
design and interpretation of acute stroke trials. The BI has a larger score­
range and therefore more possible cut-off scores compared with the 
mRS. Less is known which BI scores are corresponding with the 
different mRS scores. There have been only a few studies that 
determined pivotal BI cut-off scores and none of them were related to 
the mRS.12-14 In this article, we investigated which cut-off scores on the 




Population & Data Collection 
Data were obtained from the United States and Canadian Lubeluzole 
Ischernic Stroke Study (INT-LUB-9) and the European and Australian 
Lubeluzole Ischaernic Stroke Study (INT-LUB-5),15'1 6  provided by the 
Janssen Research Foundation (Beerse, Belgium). These trials were 
published in 1997 and 1998. In summary, these trials studied the 
neuroprotective effect of lubeluzole in acute ischaernic stroke. In both 
trials there was no significant difference in mortality rate (primary 
endpoint) between lubeluzole treated patients and placebo treated 
patients. 
The INT-LUB-5 study included 725 stroke patients (675 ischaernic / 
50 haemorrhagic) and the INT-LUB-9 included 721 patients (700 
ischaemic stroke / 21 non-ischaemic stroke or other causes). BI and 
mRS scores from ischaemic stroke patients at 1 2  weeks after stroke 
onset were analysed. Dead patients were excluded, because our analysis 
focused on disability scores of the BI and mRS. We did not make a 
distinction between lubeluzole and placebo treated patients, because the 
intention was only to study the relation between BI and mRS scores. At 
12  weeks 519 corresponding BI and mRS scores were available in INT­
LUB-9 and 51 5 in INT-LUB-5, forming a total of 1 034 BI and mRS 
scores. 
Analysis Methods 
Outcome was dichotomised into favourable and unfavourable using 
three different mRS scores, in order to obtain the corresponding BI 
score for each mRS score. A mRS score � 1 ,  2 or 3 reflected favourable 
outcome and a mRS score > 1 ,  2 or 3 reflected unfavourable outcome. 
The BI cut-off scores were defined as BI � 45 to 1 00 for favourable 
outcome and as BI < 45 to 1 00 for unfavourable outcome. Sensitivity 
was expressed as the rate of unfavourable outcome according to both 
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the mRS and BI. Specificity was expressed as the rate of favourable 
outcome according to both the BI and mRS ( see table 1). 
Table 1: Calculation of sensitivity and specificity for BI cut-off scores in 
mRS 1, 2 and 3 
BI reflecting favourable 
outcome (BI � 45 - 100) 
BI reflecting unfavourable 
outcome (BI < 45 - 100) 
mRS reflecting 
favourable outcome 






(mRS > 1, 2 or 3) 
B 
D 
A = true favourable outcome, B = false favourable outcome, C = false unfavourable 
outcome, D = true unfavourable outcome. Sensitivity = ____Q_ , Specificity = � 
B + D  A + C  
The maximal distinction between favourable and unfavourable 
outcome defined by the mRS, is reached when both the sensitivity and 
specificity of a BI score are maximal, since false favourable and false 
unfavourable outcome rates were considered to be equally important. 
This corresponds with the BI score that has the highest sum of 
sensitivity and specificity.17 To investigate the relation between sensitivity 
and specificity, receiver operator characteristic (ROC) curves were 
obtained and the areas under the curve (AUC) were calculated. ROC 
curves plot sensitivity versus 1-specificity and visualise the optimal cut­
off scores for the BI in each mRS grade. The AUC indicates the 
discriminative properties between favourable and unfavourable outcome 





Out of the 1034 patients, 547 (52.9%) were female. The mean age was 
69. 1  years (SD 12.8 years) . Median BI score was 80 with an interquartile 
range from 40 to 1 00. The mRS score distribution was: mRS 0: 9 .1 %, 
mRS 1 :  1 7. 8%, mRS 2: 1 3 . 1%, mRS 3: 1 9 . 1%, mRS 4: 29.7% and mRS 5: 
1 1 .2%. 
Sensitivity and specificity of BI and mRS cut-off scores 
The sensitivity and specificity for the cut-off scores of the BI in relation 
to mRS 1 ,  2 and 3 were calculated (table 2) and plotted in ROC curves 
(figure 1) .  
For mRS 1 the optimal cut-off score on the BI was 95,  with a 
sensitivity of 85.6% (95% CI: 82.9% - 87.9%) and a specificity of 91 .7% 
(95% CI: 87.8% - 94.5%), . For mRS 2, the BI score with the highest 
sum of sensitivity and specificity was 90 with a sensitivity of 90.7% (95% 
CI: 88 . 1  % - 92.7%) and a specificity of 88 .1  % (95% CI: 84.6% - 90,9%) . 
A mRS 3 agreed most with a BI score of 75 with a sensitivity of 95.7% 
(95% CI: 93.3% - 97.5%) and a specificity of 88.5% (95% CI: 85 .8% -
90.8%) .  In all three mRS cut-off scores, sensitivity (rate true 
unfavourable outcome) increased and specificity (rate true favourable 
outcome) decreased, when BI scores increased. 
Subsequently AUC's were calculated. The AUC for the BI cut-off 
scores was 0.932 (95% CI: 0.916  - 0.949) in mRS 1 ,  0.960 (95% CI: 0.949 
- 0.971) in mRS 2 and 0.979 (95% CI: 0.972 - 0.985) in mRS 3. 
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Table 2: Sensitivity, specificity and sumscore for BI cut-off scores in mRS 1, 2 and 3 
BI score 45 50 55 60 65 70 75 80 85 90 95 100 
Sensitivity 0.349 0.390 0.433 0.480 0.529 0.573 0.620 0.660 0.706 0.786 0,856 0,93 
mRS1 Specificity 0.996 0.996 0.996 0.996 0.993 0.993 0.978 0.971 0.960 0.935 0.917  0.813 
Sum 1 .345 1 .386 1 .429 1 .476 1 .522 1 .566 1 .598 1 .631 1 .666 1 .721 1 .773* 1 .740 
Sensitivity 0.425 0.475 0.527 0.585 0.643 0.696 0.750 0.794 0.837 0.907 0.952 0.981 
mRS2 Specificity 0.998 0.998 0.998 0.998 0.993 0.993 0.978 0.966 0.939 0.881 0.809 0.651 
N Sum 1 .423 1 .473 1 .525 1 .583 1 .636 1 .689 1 .728 1 .760 1 .776 1 .788t 1 .761 1 .632 
U1 
Sensitivity 0.61 9  0.676 0.745 0.813 0.875 0.917  0.957 0.976 0.991 1 .000 1 .000 1 .000 
mRS3 Specificity 0.995 0.984 0.979 0.967 0.948 0.923 0.885 0.846 0.794 0.691 0.596 0.460 1 �  Sum 1 .614 1 .660 1 .724 1 .780 1 .823 1 .840 1 .842+ 1 .822 1 .785 1 .691 1 .596 1 .460 
* = maximum sum of sensitivity and specificity in mRS 1 � 
t = maximum sum of sensitivity and specificity in mRS 2 � 
+ = maximum sum of sensitivity and specificity in mRS 3 � 
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Figure 1: ROC curves for BI cut-r1f scores in mRS 1, 2 and 3. 
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Discussion 
In this study we analysed the optimal cut-off scores for the BI and the 
mRS. These were found to be: BI 95 for mRS 1, BI 90 for mRS 2 and BI 
75 for mRS 3. This finding may have consequences for the definition of 
outcome in acute stroke trials. 
A recent acute stroke trial defined favourable outcome with mRS $; 2 
and BI � 75.18  According to our results, these cut-off scores could be 
suboptimal. The sensitivity (75.0%) and specificity (97.8%) of these cut­
off scores implicates that 25% percent of the patients would have a 
favourable outcome according to the BI but an unfavourable outcome 
according to the mRS. With regard to the specificity, 2.2 % would have 
an unfavourable outcome according to the BI but a favourable outcome 
according to the mRS. By choosing a BI cut-off score of � 90 (sensitivity 
90.7%, specificity 88.1 %), the false favourable outcome rate could be 
reduced to 9 .3%, where the false unfavourable outcome rate would 
increase to 11. 9%. Minimising false favourable and false unfavourable 
outcome rates could decrease unnecessary heterogeneity of outcome in 
acute stroke trials. 
Compared with our results, Celani et al, found that BI > 90 
(sensitivity 98%, specificity 97%) was a pivotal score where patients did 
not require help from another person for everyday activities.14 Kay and 
colleagues concluded that BI $; 80 (sensitivity 94%, specificity 80%) was 
the optimal cut-off score for self-reported dependency.12 These cut-off 
scores differed with those of our study when dependency is considered 
to be mRS > 2, for which the optimal BI score was < 90. These 
differences may be explained by the subjectivity of self-reported 
dependency, which will be influenced by personal circumstances such as 
socio-economic status and psychological factors. 
The mRS cut-off scores were used as a reference to distinguish 
favourable from unfavourable outcome. Although this is actually not a 
'gold standard' for dichotomising outcome, we think that the mRS is 
suitable for this purpose. Firstly, the mRS is a clinically relevant scale, 
with 6 different easily understandable and well defined grades. Secondly, 
the BI is highly correlated with the mRS,19 therefore we can compare BI 
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cut-off scores with the mRS. Thirdly, the mRS measures global disability, 
whereas the BI scores only ADL. 
A point of criticism is that there is only a 5-point difference between 
the optimal BI cut-off scores in mRS 1 and mRS 2. These BI scores are 
near the maximum score of the BL This can be explained by the 
frequently observed ceiling effects of the BI.5•6•20 Weimar and co-authors 
concluded that because of the ceiling effect the mRS is preferable to the 
BI for defining outcome. 5 Kwon et al showed that there was no 
significant difference in BI scores between mRS 0, mRS 1 and mRS 2, 
due to ceiling effects of the Bl. 19  
If the intention of a therapeutic intervention is to obtain excellent 
recovery after stroke, which could be defined as mRS � 1, the 
corresponding BI cut-off score was � 95, according to our results. There 
is consensus that mRS � 2 reflects independence and mRS > 2 
implicates dependence.21 Our study showed that a BI score � 90 is the 
optimal cut-off score in relation to mRS � 2. In severe strokes, one could 
decide to choose mRS � 3 and BI � 75 as cut-off scores for favourable 
outcome. An example of stroke-severity related outcome has been 
mentioned by Adams et al.22 They used the mRS as primary endpoint, 
where mRS cut-off scores 0, � 1 or � 2 reflected favourable outcome, 
depending on the baseline National Insititute of Health Stroke Scale 
(NIHSS) score. 
In conclusion, we have determined the optimal corresponding BI 
and mRS cut-off scores: BI 95 for mRS 1, BI 90 for mRS 2 and BI 75 
for mRS 3. We recommend the use of this / these BI cut-off score(s) 
with the corresponding mRS score(s) for future acute stroke trials, in 
which both BI and mRS scores dichotomise favourable and 
unfavourable outcome. 
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Introduction - The effectiveness of therapeutic interventions in acute 
stroke trials is traditionally measured with the modified Rankin scale 
(mRS) and the Barthel Index (BI). The mRS is a global disability scale 
divided into 6 steps from total independence to total dependence and 1 
grade for death. The BI assesses 10 basal activities of daily living, of 
which 8 assess level of dependence (bathing, grooming, using stairs, 
dressing, feeding, toilet use, transfers and walking). The aim of this study 
was to investigate the relation between the mRS and the total scores and 
item-scores of the BI. 
Methods - Three months mRS and BI scores were collected from 2 
multicentre randomised, placebo-controlled trials with lubeluzole (515 
and 519 patients). In each patient we compared the mRS grades with the 
total BI score and the scores on the 10 subitems. 
Results - For both trials there was extensive overlap of BI scores 
between mRS grades and a wide range in BI scores among patients with 
mRS grades 3 and 4. We also found discrepancies between the BI item­
scores and mRS grades. About 40% of patients with mRS grades 1 (able 
to carry out all usual activities) and 2 (able to look after own affairs 
without assistance) were not independent on at least one activity of the 
BI. In both studies, about 30% of the patients needed help or 
supervision for walking, although they were classified as mRS 3 
(requiring some help but able to walk without assistance). 
Conclusions - Investigators in stroke trials use the mRS as a subjective 
global disability scale, and they do not strictly take into account 
limitations in performing specific basal activities of daily living, as 
assessed by the BI, to assign mRS grades. 
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Introduction 
The clinical evaluation of new treatments for acute stroke is hindered by 
lack of consensus on how to assess outcome.1-3 Although stroke scales, 
such as the National Institute of Health Stroke Scale (NIHSS)4 and the 
European Stroke Scale (ESS)5 accurately measure neurological 
impairments, it is argued that recovery of neurological deficits is not 
relevant as primary endpoint.6'7 Many find that stroke therapy should 
reduce disability, especially the degree of dependence in the patient's 
own environment. 
The most frequently used instruments to measure disability and 
dependency following stroke are the modified Rankin Scale (mRS)8 and 
Barthel Index (BI).9 The mRS should be considered as a global disability 
scale,10 with 6 different grades (see Appendix 1). The mRS is a modified 
version of the original Rankin scale.1 1  Patients with a mRS score � 2 by 
definition are independent. The BI is a 10-item scale that concentrates 
on activities of daily living (bathing, grooming, ascending and descending 
stairs, bladder management, bowel management, dressing, feeding, toilet 
use, transfers and walking). Except for bladder and bowel management, 
a maximum score on the other 8 items means that a patient is fully 
independent in performing that activity. The scores of the 10 items are 
summed to a maximum possible score of 100 (independent) and 
minimum of O (totally dependent) (see Appendix 2). 
Both the mRS and BI showed good clinimetrical properties for 
measuring disability in stroke patients.6'8'1 2'1 3  Some investigators argue 
that the BI is a more reliable and less subjective scale for assessing 
disability than the mRS.1 3 On the other hand, the BI focuses on basic 
activities and lacks information on many instrumental activities of daily 
living. The aim of this study was to investigate the relationship between 
the mRS and the total BI and the 10 item-scores, in the setting of 





Data were obtained from 2 randomised multicentre trials with lubeluzole 
in patients with acute ischaemic stroke. Details of these studies were 
published in 1997 and 1998. 14'1 5  LUB-INT-5 included 725 patients and 
was conducted at 107 centres in Europe and Australia. LUB-INT-9 
included 721 patients and was conducted at 83 United States and 
Canadian centres. Both studies found that lubeluzole given within 6 
hours after stroke onset did not reduce dependency ( defined as a mRS :::; 
2 or a BI score 2 7 5) at 3 months. The mRS and BI were completed by 
qualified and trained personnel (investigators, co-investigators or trial 
nurses) during visits by face to face interviews. Precise instructions on 
how to complete the scales were given during training sessions organised 
by the study sponsor and explicitly explained in the investigators 
documents. The BI was used to describe what the patient was capable of. 
Assessing independence was based on the need of requiring help or 
supervision by another person, and was not influenced by the use of 
aids. 
We studied the relationship between the mRS and the items of the 
BI in patients with confirmed ischaemic stroke, who were alive at 3 
months and in whom both scores were available. The 10 activities of 
daily living assessed in the BI are bathing, grooming, ascending and 
descending stairs, bladder management, bowel management, dressing, 
feeding, toilet use, transfers and walking. Bowel and bladder functions 
do not actually define a level of dependence. Data were obtained from 
the Janssen Research Foundation (Beerse, Belgium). To investigate for 
possible population-based differences, we analysed each study separately. 
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Relationship between BI and mRS 
Boxplots were made to show the distribution of BI scores within each 
mRS grade. 
All mRS scores were compared with the scores on the 10 items of 
the BI. We searched for discrepancies between scores on these items and 
the assigned mRS grade. By definition, a patient needing help for a 
certain activity on one of the 8 BI-items measuring level of 
(in)dependence, should by definition have a mRS score > 2, and a 
patient unable to walk without assistance should have a mRS score > 3. 
The mRS grades were adjusted on the basis of the previously mentioned 
8 BI item-scores. 
Statistics 
The Wilcoxon signed rank test was used to investigate whether the 
distributions of reported mRS scores differed from adjusted mRS scores. 
All analyses were done with SPSS version 11.0. Statistical significance 
was defined as p <  0.05. 
Results 
For this study, 515 and 519 patients from respectively LUB-INT-5 and 
LUB-INT-9 were eligible. The mean age ± SD of the patients was 68. 7 
± 12.8 years (41.7% woman) in LUB-INT-5, and 69.5 ± 12.8 years 
(47.6% woman) in LUB-INT-9. The distribution of BI scores for each 
mRS grade is shown in figure 1A. In mRS 0, 1 and 2, the range of BI 
scores was small, with more than 90% having a score � 85. In contrast, 
the range of BI scores in mRS 3 and 4 was wide, and varied between 40-
100 and 0-85, respectively. There were considerable overlaps in BI scores 
between the mRS grades. 
In table 1, we show for each mRS grade the percentages of patients 




had maximum scores on the items of the BI. However, in LUB-INT-5 
and LUB-INT-9, respectively 1 1  % and 1 4% of the patients with mRS 1 ,  
and 2 8  % and 43 % with mRS 2 were dependent for at least one activity. 
In both studies, 31 % and 27% of the patients needed help or supervision 
for walking, although they were classified in mRS 3 (able to walk without 
assistance). In mRS 4, at least 3% could walk independently. mRS scores 
were adjusted as follow: patients with mRS scores 1 or 2, who needed 
help on any of the items of the BI ( except for bladder and bowel 
control), were assigned to mRS score 3; patients with mRS scores 1 ,  2 or 
3, who were unable to walk without help or supervision, were assigned 
to mRS score 4; patients with mRS score 4, who walked without 
assistance, were assigned to mRS score 3. After these adjustments, 17% 
and 26% with an initial mRS score 1 and 61  % and 66% with an initial 
mRS score 2 were reclassified in mRS scores 3 or 4, in respectively the 
LUB-INT-5 and LUB-INT-9. Roughly 30% of patients initially assigned 
to mRS score 3 were reclassified in mRS score 4, and about 3% of 
patients with a mRS score 4 were reclassified in mRS score 3 (table 2). 
The distribution of the adjusted mRS grades differed significantly from 
the original distribution (for both studies: p < 0.001 ). 
A reanalysis of the LUB-INT-5 and LUB-INT-9 with the adjusted 
mRS data did not change the conclusion that lubeluzole was ineffective 
in reducing disability (based on the number of patients with an adjusted 
mRS � 2; data not shown). Reanalysis of the distribution of BI scores in 
the adjusted mRS grades still showed a wide range of BI scores in mRS 
grades 3 and 4, and considerable overlaps in BI scores between the mRS 
grades (figure 1B). 
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Table 1: Items of the BI for which patients required help 1% 
I LUB-INT-5 LUB-INT-9 
mRS mRS 
Item 0 1 2 3 4 5 0 1 2 3 4 5 
Stairs 0 5.8 27.8 58.3 100 100 0 12.3 24.3 61 .8 99.3 100 
Transfers 0 0 1 .6 30.2 87.3 95.4 0 5.1 5.4 25.5 88.7 100 
Walking on level surface 0 2.3 13.1 3 1 .2 96.4 100 0 1 1 .2 14.9 27.5 96.5 100 
l,.) Bathing self 0 10.5 23.0 74.0 94.0 100 0 10.2 13.5 53.9 93.6 100 
00 
Dressing 0 7.0 27.9 72.9 92.8 100 0 14.3 43.3 67.7 95.8 100 
Feecling 0 0 31 . 1  63.5 80.7 100 0 7.1 23 .0 51 .0 85.8 94. 1 
Toilet use 0 3.5 3.3 38.5 89.8 100 0 4. 1 6.8 32.4 90.8 100 
Grooming 0 0 1 .6 31 .6 53.9 98.5 0 8.2 5.4 24.5 67.4 100 
Controlling bladder* 1 .9 4.7 9.8 10.4 48.8 96.9 0 7.1 9.5 13.7 48.2 100 
Controlling bowels* 0 2.3 0 9.4 23.5 90.8 0 0 4. 1 1 1 .8 34.5 98.0 
Values are expressed in percentages. Requiring help is defined as a non-maximal score on an item of the BL * 
The items regarcling bladder and bowel management are expressed as percentage patients that are (occasionally) 
incontinent. BI = Barthel index, mRS = modified Rankin scale. 
Relationship between BI and mRS 
Table 2: Relation between recorded and adjusted mRS 
Adjusted mRS 
Trial Recorded mRS 0 1 2 3 4 5 Total 
LUB- INT-5 0 41 41 
1 71 14 1 86 
2 24 31 6 61 
3 66 30 96 
4 6 1 60 166 
5 65 65 
Total 41 71 24 1 1 7  1 97 65 5 15  
LUB- INT-9 0 53 53 
1 72 1 6  10  98 
2 25 40 9 74 
3 72 30 102 
4 5 136 141 
5 51  51  
Total 53 72 25 133 1 85 51 5 19  
Values are expressed in numbers. mRS = modified Rankin scale. 
Discussion 
Important decisions about the effectiveness of therapeutic interventions 
in acute stroke trials are being made based on outcomes that are 
dichotomised by using the mRS. Much controversy exists about which 
endpoints on the mRS are the most suitable for evaluation of acute 
stroke trials. Most stroke trials define favourable outcome as mRS grade 
� 1 or � 2. In this study, we found that a substantial amount of patients 
with mRS grade 1 and 2 needed help for either dressing, feeding, bathing 
or climbing stairs, indicating that they were not independent. Others 
have suggested that it may be easier to define poor outcome, which 
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would correspond to a mRS score > 3.2 We found that more than 25% 
of the patients with mRS grade 3 needed help or supervision with 
walking, which would classify them into mRS grade 4. 
Although all investigators were well instructed on how to use the 
outcome scales, a possible limitation of our study was that the LUB­
INT-5 was performed in many European countries with non-native 
English speakers. Therefore, we analysed the LUB-INT-5 and LUB­
INT-9 separately. The inconsistencies between mRS grades and scoring 
on the BI items were remarkably similar in both trials. Do these 
inconsistencies mean that the mRS is unreliable? Although the intra- and 
interrater reliability were found satisfactory8, it was suggested that a 
structured interview could improve agreement between raters to assign 
grades on the mRS. 1 6'1 7  The BI was originally developed to score the 
ability of a patient with a chronic neuromuscular or musculoskeletal 
disorder to care for himself and, by repeating, to assess improvements.9 
Many tasks that are not measured with the BI may play an important role 
in determining disability after stroke. A BI of 100 (independent on all 10 
activities) does not mean that a patient is independent or able to live 
alone; e.g. he may not be able shop, use transportation, cook, keep 
house, or handle finances. This may also explain why, after re-scoring the 
mRS based on the information obtained from the BI items, there was 
still a considerable overlap between BI scores and mRS grades in both 
trials. 
According to the International Classification of Impairments 
Disability and Handicap model of the World Health Organization, the 
ideal outcome measure should take the overall condition of stroke 
patients into account.18 The American Heart Association Stroke 
Outcome Classification has developed such a model to score patients on 
both impairments and disability,1 9  but this model has never been used as 
primary outcome measure in acute stroke trials. A more simple approach 
of assessing stroke outcome is the use of the 'three simple questions'.20-22 
This model divides outcome into four categories ( dead, poor, indifferent 
and good outcome) by subsequently asking whether the patients is alive, 
requires help from anybody for everyday activities or experiences any 
problems after stroke. This model has not frequently been applied as 
outcome measure in acute stroke trials. 
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Our study suggests that the mRS in multicentre stroke trials is used 
as a subjective global disability scale, taking into account changes in 
activity and lifestyle after stroke that do not always match the basic 
activities of daily living measured by the BI. It is uncertain whether 
adjusting the mRS by a means of a structured interview or findings on 
the BI would improve its validity in measuring functional outcome after 
stroke. 
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Introduction - Hyperglycaemia in acute ischaemic stroke is traditionally 
associated with a worsened outcome. However, it is unclear whether the 
impact of hyperglycaemia on stroke outcome is similar in lacunar and 
non-lacunar infarctions. 
Methods - The relation between serum glucose measured within six 
hours after stroke onset and functional outcome was investigated in 
1,375 ischaemic stroke patients who had been included in two placebo­
controlled trials with lubeluzole. The endpoint was a favourable 
outcome, defined as a modified Rankin Scale score ::; 2 at three months. 
Classification into lacunar (n = 168) and non-lacunar (n = 1,207) strokes 
was based on clinical criteria according to the Oxfordshire Community 
Stroke Project and findings on brain CT scan. Hyperglycaemia was 
defined as blood glucose > 8 mmol/L. A possible concentration 
dependent effect of glucose on outcome was investigated in both lacunar 
and non-lacunar infarctions. 
Results - Multivariate analysis showed that hyperglycaemia was 
associated with decreased odds of a favourable outcome in non-lacunar 
stroke (OR 0.61; 95% CI 0.41-0.88, p = 0.009), but with increased odds 
of a favourable outcome in lacunar stroke (multivariate OR for glucose 
> 8 mmol/1: 2.70; 95% CI 1.01-7.13, p = 0.048). In non-lacunar stroke, 
there appeared to be a concentration-effect relation, as the odds of 
favourable outcome gradually decreased with increasing glucose levels. 
In lacunar stroke, an association with favourable outcome was observed 
with glucose levels > 8 mmol/L, but this beneficial effect diminished 
with more severe hyperglycaemia > 12 mmol/L. 
Conclusion - Hyperglycaemia is associated with unfavourable outcome 
in non-lacunar stroke, but moderate hyperglycaemia may be beneficial in 
lacunar stroke. 
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Introduction 
Several studies have identified hyperglycaemia as an independent risk 
factor for death and more severe disability following acute ischaemic 
stroke. 1 -6 Admission hyperglycaemia is common in acute stroke patients 
and exists across the range of stroke subtypes. 7 There is a great deal of 
interest in achieving glycaemic control in acute stroke patients, 8'9 and a 
large randomised controlled trial, which employs the 'Glucose­
Potassium-Insulin' infusion, is ongoing.10 However, the question is 
whether treating hyperglycaemia is warranted in all types of ischaemic 
stroke. 
In animal models of reversible focal brain ischaemia, hyperglycaemia 
consistently increased infarct size.11-13 Interestingly, however, in animals 
with end-artery infarcts hyperglycaemia had a beneficial effect and 
decreased infarct size. 14'1 5  The investigators suggested that these animal 
data might predict that lacunar infarctions would not be worsened by 
hyperglycaemia. A small study found that hyperglycaemia significantly 
increased serum levels of neuron-specific enolase (NSE), which is a 
biochemical marker for neuronal injury, in cortical strokes but not in 
lacunar strokes. 16 Bruno and co-workers analysed the relation between 
admission blood glucose (within twenty-four hours of stroke onset) and 
clinical outcome in patients enrolled in the Trial of ORG 10172 in Acute 
Stroke Treatment (TOAST), a placebo-controlled, randomised, double­
blind trial to test the efficacy of a low-molecular weight heparinoid in 
acute ischaemic stroke. They found that hyperglycaemia worsened the 
outcome in non-lacunar stroke, but not in lacunar stroke; in the placebo 
arm, hyperglycaemic patients with lacunar stroke had a better outcome 
than normoglycaemic patients. 17 This observation has not been widely 
taken into account by the medical community. 
The aim of this study was to further explore a possible different 





Data were obtained from the United States and Canadian Lubeluzole in 
Acute Ischaemic Stroke Study (LUB-INT-9).18 and the European and 
Australian Lubeluzole Ischaemic Stroke Study (LUB-INT-5).19 Both 
studies were multicentre, randomised, placebo-controlled trials that 
investigated efficacy and safety of lubeluzole in acute ischaemic stroke 
and found that lubeluzole given within six hours after stroke onset did 
not improve outcome at three months. The target population was at least 
eighteen years of age, presenting with substantial neurologic deficit 
within six hours of onset of an acute cerebral hemispheric ischaemic 
stroke. They had to be alert to or arousable by minor stimulation, and 
exhibit a significant motor deficit of the arm or leg. 
Analyses 
Blood was obtained within six hours after stroke onset, and glucose 
concentration was determined at the local study centres. In accordance 
with previous studies hyperglycaemia was defined as a blood glucose > 8 
mmol/L. 1•20 To investigate a possible concentration dependent effect, 
patients were stratified into 5 groups on the basis of increasing glucose 
levels: < 7 mmol/L, 7 -8 mmol/1, 8-10 mmol/L, 10-12 mmol/L and > 
12 mmol/L. 
Patients were divided into lacunar and non-lacunar stroke groups on 
the basis of clinical criteria according to the Oxfordshire Community 
Stroke Project (typical clinical lacunar syndrome and absence of evidence 
of cerebral cortical dysfunction)21 and findings on brain Computed 
Tomography (C1) scans performed at baseline and between four to 
seven days after admission. Stroke severity was assessed with the 
National Institute of Health Stroke Scale (NIHSS) in the LUB-INT-9 
and with the European Stroke Scale (ESS) in the LUB-INT-5. In both 
studies, baseline stroke severity was also stratified into mild, moderate or 
severe by a clinical global impression (CGI). The modified Rankin Scale 
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(mRS) was used to measure the degree of residual disability at three 
months after stroke onset. Favourable outcome was defined as mRS � 2, 
which means that a patient has no or only slight disability while 
functionally independent. 22 
Statistical methods 
For univariate analyses, Mann Whitney U or Pearson Chi square tests 
were used, where appropriate. The relation between initial stroke severity 
(CGI) and glucose levels was assessed using Kruskal Wallis tests. 
We performed logistic regression analysis to investigate whether 
hyperglycaemia was an independent predictor for functional outcome. 
We adjusted for possible confounders: age, stroke severity (CGI), 
lubeluzole/placebo treatment and diabetes. CGI was used instead of the 
stroke scales in order to analyse the pooled data of both trials. 
Interaction terms between glucose and CGI, and glucose and diabetes 
were tested. 
SPSS version 12 was used for statistical analyses. Statistical 
significance was defined as a (2-sided) p-value < 0.05. 
Results 
Out of the 1,446 patients included, 1,375 had confirmed ischaemic 
stroke, and these were the ones selected for this study. There were 168 
patients with lacunar stroke and 1207 patients with non-lacunar stroke. 
Baseline characteristics of the patients are given in Table 1. There were 
13 (8%) missing glucose values in the lacunar group and 107 (9%) in the 
non-lacunar group. At three months, 5 (3%) and 31 (3%) mRS scores 




Table 1: Patient characteristics at admission 
Lacunar (n = 168) Non-lacunar (n = 1207) p 
Mean age, years (SD) 70 (12) 70 (13) 0.442* 
Male gender 102 (61) 653 (54) 0.107 
Left hemisphere 56 (33) 558 (46) 0.002 
CGI 
- mild 26 (16) 34 (3) <0.001 - moderate 102 (61) 446 (37) 
- severe 40 (24) 727 (60) 
Mean blood glucose, 7.3 (3.3)t 7.9 (3.3):j: <0.001* mmol/1 (SD) 
< 7 mmol/L 99 (64) 573 (52) 
7 - 8 mmol/L 17 (11) 188 (17) 
8 - 10 mmol/L 18 (12) 156 (14) 
10 - 12 mmol/L 9 (6) 74 (8) 
> 12 mmol/L 12 (8) 109 (10) 
Previous hypertension 109 (65) 659 (55) 0.012 
Atrial fibrillation 21 (13) 369 (31) <0.001 
Coronary artery disease 53 (32) 450 (37) 0.148 
Diabetes 33 (20) 255 (21) 0.658 
Values are numbers (%) . SD = standard deviation. P-values calculated with Pearson x2-
test, unless otherwise indicated. t = 13 missing and :j: = 107 missing values. * = Mann 
Whitney U test. 
The distribution of glucose levels was not significantly different 
between the three categories of the CGI in lacunar stroke; median 
values: 6.3 mmol/L in mild, 6.2 mmol/L in moderate and 6.6 mmol/L 
in severe stroke (p = 0. 79). Median glucose values in the non-lacunar 
group were 6.4 mmol/L in mild, 6.8 mmol/L in moderate and 6.9 
mmol/L in severe stroke (p = 0.09). 
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LUB-INT 5 I 9 
1 446 patients 
1 375 lschaemic stroke 71 Haemorrhagic stroke 
1 68 Lacunar stroke 
1 3  missing glucose values 
5 missing mRS values 
1 50 analysed in 
multivariate analysis 
1 207 Non-lacunar stroke 
1 00 missing glucose values 
24 missing mRS values 
7 missing glucose / mRS values 
1 076 analysed in 
multivariate analysis 
Figure 1: Selection of patients for the multivariate ana!Jses. 
In the univariate analysis (Table 2) hyperglycaemia was significantly 
associated with worse outcome in the non-lacunar group, and there was 
a trend towards better outcome in the lacunar group. Less severe stroke 
and younger age were significantly associated with a favourable outcome 
in both groups. Diabetes was associated with an unfavourable outcome 
in non-lacunar stroke. 
The results of the multivariate analyses are presented in Table 3. 
Hyperglycaemia, defined as blood glucose > 8 mmol/L, was 
independently associated with an unfavourable outcome in non-lacunar 
stroke (OR 0.61; 95% CI 0.41-0.88, p = 0.009), but with favourable 
outcome in lacunar stroke (2.70; 95% CI 1.01-7.13, p = 0.048) (Table 3). 
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Favourable Unfavourable OR (95%CI) outcome (n=84) outcome (n=79) 
24 (31)t 14 (19):j: 1 .9 (0.9-4. 1) 
51  (61) 49 (62) 0.9 (0.5-1 .8) 
67 (14) 73 (9) -* 
1 8  (21) 6 (8) 10.0 (3.1 -33) 1 
57 (68) 43 (54) 4.4 (1 .9-10.3)2 
9 (1 1) 30 (38) 
25 (30) 28 (35) 0.8 (0.4-1 .5) 
1 5  (1 8) 1 8  (23) 0.7 (0.3-1 .6) 
57 (68) 50 (63) 1 .2 (0.6-2.3) 
53 (63) 38 (48) 1 .8 (1 .0-3.4) 
Non-lacunar 
Favourable Unfavourable OR (95%CI) outcome (n=329) outcome (n=847) 
65 (22)§ 267 (34)1 0.5 (0.4-0.7) 
174 (56) 448 (53) 1 . 1  (0.9-1 .4) 
65 (15) 73 (1 1) -* 
21 (6) 12 (1) 9.4 (4.5-19.7) 1 
197 (60) 236 (28) 4.5 (3.4-6.0)2 
1 1 1  (34) 599 (71) 
1 53 (47) 393 (46) 1 .0 (0.8-1 .3) 
55 (17) 1 93 (23) 0.7 (0.5-0.9) 
174 (53) 466 (55) 0.9 (0.7-1 .2) 
1 63 (50) 431 (51) 0.9 (0.7-1 .2) 
Values are numbers (%) . Favourable outcome means a modified Rankin score of 0-2. Hyperglycaemia defined as > 8 mmol/1. 
OR = odds ratio (95% confidence intervals) . CGI = clinical global impression of stroke severity. * Mann Whitney U test, P < 
0.001 .  t = 7 missing, :j: = 6 missing, § = 33 missing and 1 = 67 missing values. 1 Odds ratio's comparing mild with severe stroke. 
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Concentration dependent effects of glucose levels as assessed with 
multivariate analyses are shown in Figure 2. In the non-lacunar infarction 
group, there was a concentration dependent effect of higher glucose 
levels and lower odds of favourable outcome. In the lacunar group, the 
association with better outcome was mainly observed for glucose levels 
between 8 and 12 mmol/L, and diminished with levels above 12 
mmol/L. There were no significant interactions between hyperglycaemia 
and CGI or diabetes in both the lacunar (p = 0.09; p = 0. 32) and non­
lacunar groups (p = 0.79; p = 0.41). In all regression models, higher age 
and more severe stroke were significant risk factors for an unfavourable 
outcome, but diabetes and lubeluzole treatment were not. 
Table 3: Multivariate analysis: predictors for favourable outcome 
Lacunar Non-lacunar 
OR 95% CI p OR 95% CI p 
Hyperglycaemia* 2.70 1 .01 - 7 .13 0.048 0.60 0.41 - 0.88 0.009 
Age (years) 0.94t 0.91 - 0.97 <0.001 0.95t 0.94 - 0.97 <0.001 
CGI 0.2H 0.10 - 0.42 <0.001 0.23+ 0 .17 - 0.30 <0.001 
Diabetes 0.44 0 .15 - 1 .29 0.133 1 .00 0.66 - 1 .53 0.993 
Lubeluzole 2.03 0.94 - 4.37 0.072 1 .01 0.75 - 1 .36 0.963 
Hyperglycaemia defined as blood glucose > 8 mmol/1. Favourable outcome means a 
modified Rankin score of 0-2. t Odds ratio for each year increase. + Odds ratio for each 
increase in stroke severity. 
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ORs for favourable outcome 
D Lacunar 
• Non-lacunar 
1 0  
� 1 -+--,......r----+-=F----+-...-----+---
0.1 7-8 8-1 0 1 0-1 2 >1 2 
Glucose concentration (mmol/L) 
Reference category: glucose < 7 mmol/L 
Figure 2: "Relation between glucose levels and functional outcome in lacunar and 
non-lacunar stroke. Acfjusted for clinical global impression, age, lubeluzole treatment 
and diabetes. 
Discussion 
This study confirms the detrimental effect of hyperglycaemia in non­
lacunar stroke, and replicates the findings by Bruno and coworkers that 
hyperglycaemia has no adverse effect on functional outcome in lacunar 
stroke; instead it may have a beneficial effect in this type of stroke.17 In 
our study, the association of hyperglycaemia and favourable functional 
outcome in lacunar stroke was independent of stroke severity, age, 
diabetes and treatment with lubeluzole. In the TOAST study population 
a significant favourable effect on lacunar stroke was demonstrated only 
in the placebo group.17  Although limited by low patient numbers, 
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stratification of patients on the basis of increasing glucose levels 
suggested that the beneficial effect in lacunar stroke may be confined to 
moderate hyperglycaemia, as it diminished with glucose levels above 1 2  
mmol/L. In non-lacunar stroke, a concentration-dependent effect was 
observed, in a sense that increasing glucose levels decreased the chance 
of favourable outcome. 
These findings may have important consequences for the treatment 
of hyperglycaemia in acute ischaemic stroke. Currently, the Glucose 
Insulin in Stroke Trial (GIST) is investigating whether glycaemic control 
in patients with acute stroke improves outcome. Patients with acute 
stroke, including lacunar infarctions, who are found to have raised 
plasma glucose > 6.0 mmol/1, are treated with a controlled infusion of 
glucose/potassium/insulin to maintain glucose at 4-7 mmol/L.10 There 
is interest in setting up additional acute stroke studies using insulin 
infusion therapy. 8'9 It is important to define the stroke type because 
treating hyperglycaemia to levels < 7 mmol/L may not be necessary in 
lacunar infarctions, where, based on animal experiments, 14•1 5  it might 
adversely affect outcome. A standard symptom list could be used for this 
purpose, which has been validated to distinguish between different 
stroke subtypes in the acute phase.23 
Infarct size and outcome in cortical stroke is highly dependent on 
collateral circulation and the fate of the hypoperfused but still viable 
brain tissue, the penumbra. By using perfusion-weighted and diffusion­
weighted magnetic resonance imaging, Parsons and colleagues showed 
that hyperglycaemia in patients with acute ischaemic stroke had a 
detrimental effect on the penumbra and led to an increased infarct size. 6 
Lacunar strokes are located in end-arteriolar vascular territories, with no 
collateral supply. Studies with diffusion weighted MRI and magnetic 
resonance spectroscopy suggest that a metabolically compromised area 
surrounding subcortical infarctions also exists.24 
The detrimental effects of hyperglycaemia on the cortical penumbra 
are not clearly understood, but can include increasing tissue acidosis 
secondary to anaerobic glycolysis, increased blood-brain barrier 
permeability, and vascular changes.1 1 '25'26 In the vasculature 
hyperglycaemia causes a pro-vasoconstrictive, pro-thrombotic and pro­
inflammatory phenotype, which severely comprorruses the 
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microvasculature and collateral circulation, and enhances reperfusion 
injury.26 Lacunar stroke associated with limb weakness, such as in our 
study, is situated in white matter and damages axons and glial cells. 
Lactate produced by astrocytes is an important rescue source of energy 
for axons27 and perhaps also for oligodendrocytes. 28 Therefore, it is 
tempting to speculate that increased lactate production due to 
hyperglycaemia in lacunar ischaemia might fuel and salvage axons and 
oligodendrocytes. 
A strong point of this study is that all patients were well 
documented, and that blood glucose was measured within six hours of 
stroke onset. A limitation of the study is the relatively low number of 
patients with lacunar strokes and the fact that the study was not powered 
to detect effects of hyperglycaemia. 
In conclusion, our study suggests that moderate hyperglycaemia in 
acute lacunar stroke may be associated with favourable outcome. This 
finding stresses the need to distinguish lacunar stroke from cortical 
stroke in an early stage, especially when therapies to normalise blood 
glucose are considered. 
References 
1 .  Weir CJ, Murray GD, Dyker AG, Lees KR. Is  hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up 
study. BM] 1997; 314(7090):1303. 
2. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and 
prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. 
Stroke 2001 ;  32(10):2426-2432. 
3. Woo E, Chan YW, Yu YL, Huang CY. Admission glucose level in relation to 
mortality and morbidity outcome in 252 stroke patients. Stroke 1 988; 19(2): 185-
191 .  
4. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of 
hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1 990; 4 7 (1 1): 1 174-1 1 77. 
54 
Hyperglycaemia and ischaemic stroke-subtype 
5. I<iers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC, Carlin J, Ratnaike S. 
Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosu1l; Psychiatry 1992; 55( 4):263-270. 
6. Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress 
BM, Davis SM. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol2002; 52(1):20-28. 
7. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. 
Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet 1999; 353(9150):376-377. 
8. Walters MR, Weir CJ, Lees KR. A randomised, controlled pilot study to investigate 
the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis 2006; 22(2-3):116-122. 
9. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion 
therapy. Stroke 2006; 37(1):267-273. 
10. Major ongoing stroke trials. Stroke 2002; 33(10):2525-2535. 
11. Anderson RE, Tan WK, Martin HS, Meyer FB. Effects of glucose and PaO2 
modulation on cortical intracellular acidosis, NADH redox state, and infarction in 
the ischemic penumbra. Stroke 1999; 30(1):160-170. 
12. Gisselsson L, Smith ML, Siesjo BK. Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab 1999; 19(3):288-297. 
13. Lin B, Ginsberg MD, Busto R. Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations. Acta 
Neuropathol (Ber� 1998; 96(6):610-620. 
14. Ginsberg MD, Prado R, Dietrich WD, Busto R, Watson BD. Hyperglycemia 
reduces the extent of cerebral infarction in rats. Stroke 1987; 18(3):570-574. 
15. Prado R, Ginsberg MD, Dietrich WD, Watson BD, Busto R. Hyperglycemia increases infarct size in collaterally perfused but not end-arterial vascular territories. 
J Cereb Blood Flow Metab 1988; 8(2):186-192. 
16. Suiter G, Elting JW, De Keyser J. Increased serum neuron specific enolase 
concentrations in patients with hyperglycemic cortical ischemic stroke. Neuroscience Letters 1998; 253(1):71-73. 
17. Bruno A, Biller J, Adams HP, Jr., Clarke WR, Woolson RF, Williams LS, Hansen 




18. Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian 
Lubeluzole Ischemic Stroke Study Group. Stroke 1997; 28(12) :2338-2346. 
19. Diener H. Multinational randomised controlled trial of lubeluzole in acute 
ischaemic stroke. Cerebrovasc Dis 1998; 8(3):172-181. 
20. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina 
A, Quintana M. Effects of admission hyperglycemia on stroke outcome in 
reperfused tissue plasminogen activator-treated patients. Stroke 2003; 34(5) :1235-
1240. 
21. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural 
history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 
337(8756) :1521-1526. 
22. Uyttenboogaart M, Stewart RE, Vroomen PC, De Keyser J, Luijckx GJ. 
Optimizing cutoff scores for the Barthel index and the modified Rankin scale for 
defining outcome in acute stroke trials. Stroke 2005; 36(9):1984-1987. 
23. Aerden L, Luijckx GJ, Ricci S, Hilton A, Kessels F, Lodder J. Validation of the 
Oxfordshire Community Stroke Project syndrome diagnosis derived from a 
standard symptom list in acute stroke. J Neurol Sci 2004; 220(1-2):55-58. 
24. Labelle M, Khiat A, Durocher A, Boulanger Y. Comparison of metabolite levels 
and water diffusion between cortical and subcortical strokes as monitored by MRI 
and MRS. Investigative Radiology 2001; 36(3) :155-163. 
25. Dietrich WD, Alonso 0, Busto R. Moderate hyperglycemia worsens acute blood­
brain barrier injury after forebrain ischemia in rats. Stroke 1993; 24(1):111-116. 
26. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular 
perspective. J Cereb Blood Flow Metab 2006;[Epub ahead of print] . 
27. Brown AM, Tekkok SB, Ransom BR. Glycogen regulation and functional role in 
mouse white matter. ] Pf?ysiol2003; 549(Pt 2) :501-512. 
28. Sanchez-Abarca LI, Tabernero A, Medina JM. Oligodendrocytes use lactate as a 
source of energy and as a precursor of lipids. Glia 2001; 36(3):321-329. 
56 
CHAPTER S 
Safety of routine intravenous 
thrombolysis between 3 and 4.5 hours 
after ischaemic stroke 
Maarten Uyttenboogaart, 1 Patrick C. Vroomen, 1 Rqy E. Stewart/ Jacques De 
Kryse0 
1 Gert-] an Lufjckx1 
From the Departments of Neurology1 and Health Sciences2, University 
Medical Center Groningen, Groningen, The Netherlands 
Adapted from the Journal of the Neurological Sciences 2007; 254: 28-32 




Introduction - The administration of recombinant tissue plasminogen 
activator (rtP A) has been proven effective for ischaemic stroke within 3 
hours after onset. A pooled-analysis of six trials showed that intravenous 
rtP A still improves outcome when given between 3 to 4.5 hours after 
stroke onset. On the basis of this pooled analysis, rtP A was also 
routinely offered to our patients between 3-4.5 hours. We report the 
safety and clinical features of this group together with the features of the 
group given rtP A within 3 hours. 
Methods - Patient characteristics, stroke severity, stroke subtype, 
incidence of symptomatic intracerebral haemorrhage (SICH), in-hospital 
mortality, and 3-months modified Rankin Scale scores (mRS) were 
prospectively registered. Data was analysed separately for patients treated 
within 3 hours ( early group) and those treated between 3-4.5 hours (late 
group). 
Results Among 17 6 patients who underwent intravenous 
thrombolysis, 101 were treated in the early group and 75 in the late 
group. Six (5.9%; 95% CI 2.8% - 12.3%) patients in the early group and 
4 (5.3%; 95% CI 2.2% - 12.9%) in the late group developed SICH (p = 
1.0). In the early group 13 (12.9%; 95% CI 7.7% - 20.8%) patients died 
within 7 days after admission, compared to 5 (6.7%; 95% CI 3.0% -
14.7%) in the late group (p = 0.179). In the early group 44 (43.6%; 95% 
CI 43.3% - 53.3%) were functionally independent (mRS � 2) at three 
months, compared to 36 (48.0%; 95% CI 37.0% - 59.1 %) in the late 
group (p = 0.559). 
Conclusions - Our data show no trend of decreased safety of 
thrombolysis beyond 3 hours. Due to a small sample size a harmful 
effect cannot be excluded but seems unlikely. 
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Introduction 
The rationale for thrombolytic therapy in acute ischaemic stroke is based 
on the concept that early reperfusion may salvage ischaemic brain-tissue. 
The National Institute of Neurological Disorders and Stroke (NINDS) 
study showed that treatment with intravenous recombinant tissue 
plasminogen activator (rtP A) was effective within 3 hours after onset of 
ischaemic stroke.1 Two other trials with intravenous rtP A, the European 
Cooperative Acute Stroke Study (ECASS)-I and ECASS-Il,2'3 which had 
a time window of 6 hour, yielded less convincing results. The Alteplase 
ThromboLysis for Acute Noninterventional Therapy in Ischaemic 
Stroke (ATLANTIS) trial,4 failed to show a beneficial effect of rtP A 
administration within a 3-5 hour time window. 
Thrombolysis with rtP A has become standard treatment for eligible 
patients with an ischaemic stroke within 3 hours after onset of 
symptoms. Unfortunately, many patients still arrive at the hospital 
beyond the 3 hour time window. s-s Extending the time window would 
allow more ischaemic stroke patients to benefit from intravenous rtP A 
treatment. A pooled analysis of individual-patient data showed that rtP A 
given between 3 and 4.5 hours after stroke onset is still effective, without 
an increased risk of haemorrhage.9 We decided that based on the 
evidence of this pooled analysis, thrombolysis could be offered to 
patients off-license in the 3-4.5 hour interval. However, concerns exist 
about the safety of this procedure beyond 3 hours in daily clinical 
practice. 
In this paper, we aim to describe our experiences with thrombolysis 
in the 3-4.5 hour time window (late group) in daily clinical practice and 





Protocol for rtPA treatment 
Since the results of the pooled analysis of the NINDS, ECASS and 
ATLANTIS rtPA trials were communicated at the 27th International 
Stroke Conference in February 2002 (San Antonio, Texas), the time 
window for routine intravenous rtP A treatment in ischaemic stroke 
patients in our clinic was extended to 4.5 hours .  As part of the 
thrombolysis protocol, informed consent was obtained from each patient 
or from his or her relative in case of patient's inability, after explaining 
the off-license use of rtPA in case of treatment in the late group. A brain 
CT scan was performed prior to thrombolysis. 
For patients presenting within 3 hours of stroke onset, we adopted 
the NINDS study protocol. For patients in the late group, we used the 
ECASS II protocol. In specific, we excluded patients in the late group 
with early ischaemic changes (EIC) exceeding one third of the middle 
cerebral artery (MCA) territory on the initial brain CT-scan. EIC were 
defined as effacement of cerebral sulci, loss of gray /white matter 
differentiation, and parenchymal hypodensity, according to the ECASS 
criteria. 3 In contrast to the ECASS II, we did not exclude patients older 
than 80 years. 
Neurological deficit was recorded with the National Institute of 
Health Stroke Scale (NIHSS). Stroke-subtypes were defined into total 
anterior circulation infarcts (TACI), partial anterior circulation infarcts 
(PACI), lacunar infarcts (LACI) and posterior circulation infarcts 
(POCI) . 10 All patients underwent a routine blood investigation and 
electrocardiography. Patients were treated with intravenous alteplase 0.9 
mg/kg to a maximum of 90 mg. Ten percent of the total dose was given 
as a bolus in 1-2 min and the remaining 90% was given in the next hour. 
Patients were monitored in a stroke unit, where early rehabilitation was 
started by a multidisciplinary team. We did not routinely perform a brain 
CT scan after each thrombolysis. Before the initial brain CT scan, the 
radiologist was informed about affected side of neurological deficit, but 
was unaware of the onset to treatment time. All initial brain CT scans 
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were reassessed for this study with the assessor blinded for the outcome 
of thrombolysis. 
Hypertension was defined as a self-reported history of hypertension 
or use of anti-hypertensive medications, or a blood pressure consistently 
measured above 140/90 mm Hg. Diabetes was defined as a self-reported 
history of diabetes, or use of medications for diabetes, or an elevated 
fasting blood glucose > 7 .1 mmol/1. Hyperlipidaemia was defined as a 
self-reported history of hyperlipidaemia or use of medications against 
hyperlipidaemia, or a serum cholesterol > 6.5 mmol/1 or a serum LDL > 
3.5 mmol/1 
Outcome measures 
For the safety analysis, we defined the following outcome measures: 
incidence of symptomatic intracerebral haemorrhage (SICH) and early 
in-hospital mortality within 7 days. SICH was defined as a neurological 
deterioration (NIHSS increment � 4 points) within 36 hours following 
thrombolysis with an intraparenchymal hematoma demonstrated by 
brain CT scan, according to the Safe Implementation of Thrombolysis in 
Stroke Monitoring Study (SITS-MOS1) definition.1 1  The modified 
Rankin Scale (mRS) score at 3 months was assessed with a structured 
interview12  by a trained stroke nurse. The mRS was dichotomised into 0-
2 (favourable outcome) and 3-6 (unfavourable outcome). Data were 
analysed separately in the early and late group and compared between 
both groups. 
Statistical analysis 
All statistical analyses were done using SPSS version 1 1 .0. The Mann­
Whitney U test was used for continuous and ordinal variables, and the X2 
test or Fisher exact test for dichotomous variables. Predictors for 
unfavourable outcome were obtained with an univariate analysis and a 
multivariate analysis using a logistic regression approach. A threshold of 
p < 0.2 was chosen to select variables from the univariate analysis for the 
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logistic regression model, except for "onset to treatment time" (OTI), 
which was included regardless of the p-value. 
Results 
Baseline characteristics 
Between April 2002 and April 2005, 826 consecutive ischaemic stroke 
patients were admitted to our department, of whom 176 (21 %) received 
rtP A treatment. Baseline characteristics for the early and late group are 
presented in table 1. In 57 % of the patients treatment was started within 
3 hours. Patients in the early group had a significantly higher NIHSS 
score and a higher frequency of TACI compared with patients in the late 
group. Three patients (4. 1  %) in the late group had EIC in more than 
one-third of the MCA territory, when the CT scans were reassessed. 
These were considered protocol violations. 
Outcome 
SICH occurred in the early group in 6 patients (5.9%; 95% CI 2.8% -
12.3%), of whom 4 died, and in the late group in 4 patients (5.3%; 95% 
CI 2.2% - 12.9%), of whom 3 died (p = 1.0). Presence of EIC in more 
than one-third of the MCA territory in the late group was associated with 
SICH: 2 of the 3 patients with EIC in more than one-third of the MCA 
territory developed SICH, compared with 2 out of the remaining 70 
patients (p = 0.007). In the early group, however, the presence of EIC in 
more than one-third of the MCA territory was not associated with SICH 
(0/7 versus 6/94, p = 1.0). Multivariate analysis showed that, after 
adjustment for age, gender, NIHSS, EIC, glucose concentration and 
stroke subtype, treatment in the late group was not associated with SICH 
(OR 1.03; 95% CI 0.26 - 4.02). 
62 
Thrombo/ysis between 3 and 4.5 hours 
Table 1: Baseline characteristics 
Early group (0-3 h) Late group (3-4.5 h) 
Characteristic n = 101 n = 75 p 
Mean age (SD), years 68 (14) 66 (15) 0,473* 
Male 51 (50) 45 (60) 0.210 
Median NIHSS score (range) 14 (2-23) 12 (2-35)t 0.025* 
Median OTT (range), min 150 (30-180) 220 (185-270) <0.001* 
Stroke-subtype 
TACI 42 (42) 18 (24)t 0.010 
PACI 44 (44) 39 (53)t 0.215 
LACI 13 (13) 13 (18)t 0.409 
POCI 2 (2) 4 (5)t 0.404:j: 
Mean SBP (SD), mm Hg 153 (24)t 157 (24)t 0.185* 
Mean DBP (SD), mm Hg 83 (14)t 86 (18)t 0.187* 
Mean glucose (SD), mmol/1 6.2 (1.5)t 6.8 (2.5)t 0.519* 
Computed tomography findings 
Midline shift 2 (2) 0 (0)§ 0.510:j: 
EIC 46 (46) 28 (38)§ 0.344 
EIC > 33% of MCA 7 (7) 3 (4)§ 0.522:j: 
Dense artery sign 23 (23) 14 (19)§ 0.567 
Normal 29 (29) 29 (40) § 0.128 
Vascular risk factors 
Hypertension 47 (47) 34 (45) 0.874 
Diabetes 11 (11) 9 (12) 0.819 
Hyperlipidaemia 27 (27)t 21 (29)§ 0.798 
Atrial fibrillation 25 (25) 22 (29) § 0.430 
Previous stroke / TIA 12 (12) 16 (21) 0.090 
Prior use of antiplatelets 29 (29) 19 (25) 0.619 
Values are given in numbers (%) and p-values calculated with X2 test, unless otherwise 
indicated. * Mann-Whitney U test, t 1 missing value, :j: Fisher exact test, § 2 missing 
values. SD = standard deviation, NIHSS = NIH stroke scale, OTT = onset to 
treatment time, TACI / PACI = total / partial anterior circulation infarcts, LACI = 
lacunar infarcts, POCI = posterior circulation infarcts, SBP / DBP = systolic / 
diastolic blood pressure, EIC = early ischaemic changes, MCA = middle cerebral artery, 
TIA = transient ischaemic attack. 
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Table 2: Predictors of an unfavourable outcome after thrombolysis I Q 
Favourable Unfavourable I 'v-i 
outcome outcome Unadjusted p Adjusted OR p 
(n = 80) (n = 96) OR 
Male 44 (55) 52 (54) 0.97 (0.53 - 1 .76) 0.912 
Age � 80 years 9 (1 1) 33 (34) 4. 13  (1 .84 - 9.30) <0.001 6.05 (2.39 - 15.31) <0.001 
NIHSS score > 13  12  (29) 59 (62)* 4.06 (2. 1 5  - 7.68) <0.001 3.80 (1 .74 - 8.31) 0.001 
OTT > 3 hours 36 (45) 39 (41) 0.84 (0.46 - 1 .52) 0.559 1 . 1 3  (0.53 - 2.41) 0.753 
°' Mean glucose (SD) . 6.3 (2) 6.6 (2):j: 0. 1 96 1 . 10  (0.91 - 1 .32) 0.324 ..p.. 
Mean SBP (SD), mmHg 154.0 (23) 155.6 (28):j: 0.832 
Mean DBP (SD), mm Hg 86.5 (16) 82.3 (16):j: 0.087 0.99 (0.97 - 1 .01) 0.377 
Diabetes 8 (10) 12 (13) 1 .29 (0.50 - 3.32) 0.603 
Hypertension 34 (43) 47 (49) 1 .30 (0.71 - 2.36) 0.392 
Atrial fibrillation 21 (26)* 26 (27)* 1 .04 (0.53 - 2.04) 0.907 
Previous stroke 17  (21) 1 1  (1 1) 0.48 (0.21 - 1 . 10) 0.077 0.62 (0.23 - 1 .67) 0.347 
Non-lacunar stroke 61 (77)* 88 (92) 3.25 (1 .33 - 7.94) 0.007 1 .80 (0.60 - 5.41) 0.295 
°' 
u, 
Table 2: Continued 
Favourable Unfavourable Unadjusted outcome outcome p Adjusted OR p 
(n = 80) (n = 96) OR 
EIC on CT scan 24 (30) 50 (53):j: 2.65 (1.42 - 4.96) 0.002 2.69 (1.08 - 6.70) 0.034 
Dense artery sign 13 (16) 24 (26):j: 1.77 (0.83 - 3.75) 0.136 1.44 (0.55 - 3.81) 0.459 
Normal CT scan 33 (41) 25 (27):j: 0.52 (0.27 - 0.98) 0.041 1.80 (0.66 - 4.91) 0.248 
OR = Odds ratio (95% CI). SD = standard deviation. NIHSS = NIH stroke scale. OTT = onset to treatment time. SBP = 
systolic blood pressure. DBP = diastolic blood pressure. EIC = early ischaemic changes. Stroke subtype was dichotomised 











The early in-hospital mortality rate was 12.9% (95% CI 7.7% -
20.8%; n = 1 3) in the early group and 6.7% (95% CI 3.0% - 14.7%; n = 
5) in the late group (p = 0. 1 79) . Variables associated with early in­
hospital mortality in an univariate analysis were: EIC (12 (dead)/74 (with 
EIC) versus 6 (dead)/ 100 (without EIC) , p = 0.029) , EIC in more than 
one-third of the MCA territory (5/ 1 0  versus 13/1 64, p = 0.001), NIHSS 
score > 13 (14/82 versus 4/93, p = 0.006) and TACI (1 3/56 versus 
5/120, p < 0.001) .  
The baseline NIHSS and frequency of TACI were different in early 
and late groups .  However, after adjustment for NIHSS score and 
frequency of TACI, treatment in the late group did not predict SICH 
(OR 0.98; 95% CI 0.26 - 3.73) or early death (OR 0.63; 95% CI 0. 1 9  -
2. 1 3) .  
Forty-four (43.6%; 95% CI 43.3% - 53.3%) patients in the early 
group and 36 (48.0%; 95% CI 37.0% - 59. 1 %) patients in the late group 
were independent (mRS � 2) at 3 months (p = 0.559) .  Very favourable 
outcome (mRS � 1) was also not different between the early and late 
group: 28 (27.7%; 95% CI 19 .3% - 37.5%) versus 25 (33.3%; 95% CI 
22.9% - 45.2%),  respectively (p = 0.422) . 
Twenty (1 9 .8%; 95% CI 12.5% - 28.9%) patients treated in the early 
group were dead after 3 months, compared to 1 0  (1 3 .3% 95%; CI 6.6% 
- 23.2%) in the late group (p = 0.259) .  Of the variables associated with 
unfavourable outcome in the univariate analysis (table 2), three predicted 
outcome in a multivariate analysis: NIHSS score > 1 3, age � 80 years and 
presence of EIC. 
Discussion 
This paper reports our experiences with the routine administration of 
thrombolysis with rtP A between 3 and 4.5 hours after stroke onset. We 
found no difference in the occurrence of SICH and early in-hospital 
mortality between the sub-3 hour and 3-4.5 hour groups. We observed a 
similar incidence of SICH (5.7%) and early in-hospital mortality (9.7%) 
in thrombolysing up to 4.5 hours as those reported in the NINDS study1 
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and other rtP A registries, 7•1 3-20 where most patients were treated within 3 
hours. In the ATLANTIS trial,4 7.0% of the rtPA treated patients in the 
3-5 hour time window had a SICH, compared to 5.3% in our cohort. 
In patients treated beyond 3 hours, the presence of EIC more than 
one-third of MCA territory was associated with the development of 
SICH. Although the numbers are low, these findings again suggest that 
rtP A should not be used beyond 3 hours in patients with a brain CT 
showing EIC more than one-third of the MCA territory. Within 3 hours, 
major EIC changes were not associated with an increased risk of SICH. 
This is consistent with the observation from Patel et al, who found no 
increased risk of intracerebral haemorrhage in patients with EIC treated 
within 3 hours after onset. 21 This finding, however, was not confirmed 
by Tanne and co-workers.22 
A substantial number of ischaemic stroke patients may benefit from 
intravenous rtP A treatment by extending the time window to 4.5 hours. 
In our cohort, about 1 in 5 of all admitted ischaemic stroke patients were 
treated with rtP A, which is a higher proportion than reported in previous 
studies. 7,14,1 6,1 7,t 9 
Our study is not suited and was not intended to compare 
effectiveness because of the lack of a placebo group. However, the 
pooled trial data from the six pivotal randomised placebo-controlled 
rtP A trials suggest some effectiveness after 3 hours; the odds of a 
favourable outcome decreased from 2.8 (95% CI 1.8 - 4.5) for treatment 
within O to 1.5 hours, 1.5 (95% CI, 1.1 - 2.2) for treatment between 1.5 
and 3 hours and 1.4 (95% CI, 1.1 - 1.9) between 3 and 4.5 hours. After 
4.5 hours the lower limits of the 95% CI for the odds of a favourable 
outcome cross 1.0 and the benefit of therapy become small and lack 
significance. 9 
Older age, higher NIHSS score, and presence of EIC on the CT 
scan were independent predictors of unfavourable outcome, which is in 
accordance with previous reports.1 5'23 The incidence of EIC the early and 
late group together ( 42%) was higher compared to the NINDS (31 % )21 
but comparable with the ECASS I (43%).24 
The present study has limitations. Firstly, the small sample size has 
led to wide confidence intervals around the point estimates. No trend 
towards increased risk of thrombolysis beyond three hours was found, 
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however. Secondly, safety and outcome data may be biased because of a 
lack of a placebo-controlled design. Even though some significant 
imbalances (NIHSS, number of T ACI) between the two cohorts were 
corrected for, this does not guarantee the exclusion of all relevant bias. 
Thirdly, the results were obtained from a single-center that serves as 
regional stroke referral centre. Since safety and efficacy of thrombolysis 
depends much on the experience of a given center25, our result may have 
a limited generalisability. Fourthly, we performed no routine brain CT 
scans after thrombolysis, therefore we could not study the incidence of 
asymptomatic intracerebral haemorrhages in the early and late group. 
The safety of thrombolytic therapy for stroke in daily practice in 
Europe has been monitored 1n the Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOS1), but this 
registry, in which we participate, concerns only stroke patients that are 
treated within 3 hours. Therefore more studies are required that 
investigate the safety and efficacy of rtP A beyond 3 hours with 
stratification for stroke severity. The results of this study are an extra 
argument to participate in further studies because the results of our study 
suggest that thrombolysis between 3 and 4.5 hour is safe. The ECASS 
III, an ongoing double blind randomised placebo-controlled trial, 
investigates the efficacy and safety of rtP A in the 3-4.5 hour time 
window. The Third International Stroke Trial (IST-3) is another ongoing 
trial, which includes patients from O - 6 hours after stroke onset. The 
role of perfusion and diffusion weighted imaging on magnetic resonance 
imaging (MRI) for selecting eligible stroke patients for rtP A, is 
investigated in Echoplanar Imaging Thrombolysis Evaluation Trial 
(EPITHE1). The Desmoteplase in Acute Ischaemic Stroke Trial II 
(DIAS II), investigates the efficacy and safety of desmoteplase in acute 
stroke and selects patients on the basis of perfusion / diffusion 
mismatch on brain MRl/CT imaging. 
In summary, efforts should be continued to treat eligible stroke 
patients with rtP A as soon as possible, but some patients will continue to 
arrive beyond the recommended 3 hour time window. Based on the 
pooled-analysis, these patients could still benefit from intravenous rtP A 
when given before 4.5 hours. Our study suggests that in a routine clinical 
setting, intravenous rtP A treatment between 3 and 4.5 hours has a safety 
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profile comparable with treatment within 3 hours, but strict adherence to 
the ECASS II, especially with regard to the presence of EIC on brain 
CT, criteria and treatment by an experienced acute stroke team is 
mandatory. 
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Introduction: Treatment with recombinant tissue Plasminogen 
Activator (rtP A) has been proven effective for ischaemic stroke within 3 
hours after onset. Little is known regarding safety and outcome in 
patients aged 2:: 80 years because this age group was underrepresented in 
clinical trials. 
Methods: In a prospective patient registry we collected patient 
characteristics, symptomatic intracranial haemorrhage rate (SICH), early 
in-hospital mortality and 3 months outcome after rtP A treatment. These 
data were analysed separately for patients 2:: 80 years and their younger 
counterparts. Functional outcome was measured with the modified 
Rankin Scale (mRS). 
Results: 142 consecutive patients were treated. 111 patients (78%) were 
younger than 80 years and 31 (22%) 2:: 80 years. SICH occurred in 4 
patients < 80 years (3.6%; 95% CI 1.4-8.9) and in 3 patients 2:: 80 years 
(9.7%; 95% CI 3.3-24.9), p=0.18. The early in-hospital mortality rate was 
comparable between younger (11 %) and older patients (13%), p = 0.75. 
After 3 months the mortality rate in the elderly was significantly higher 
(p<0.001), and incidence of functional independence significantly lower 
(p<0.004). 
Conclusions: Currently there is no evidence that stroke patients 2:: 80 
years are at greater risk for SICH after rtPA treatment than their younger 
counterparts. Robust efficacy data are lacking and a randomised placebo­
controlled trial is required to investigate whether rtP A treatment in this 
age group improves outcome. 
74 
Thrombo!Jsis in the elder!J 
Introduction 
Treatment with intravenous recombinant tissue plasminogen activator 
(rtP A) in acute ischaemic stroke has been shown to improve outcome. 1 
Little is known regarding the safety and efficacy of this treatment in 
patients aged 80 years and older, because this age group was 
underrepresented in clinical trials.1-4 The NINDS trial1 was the only trial 
without age limit and only 7% (n=42) of the included patients were older 
than 80 years. However, about 30% of admitted ischaemic stroke 
patients are older than 80 years. 5 
A number of previous observational studies compared the outcome 
of rtP A treatment in patients older than 80 years with their younger 
counterparts,6-12 and a recent systemic review suggested that rtPA is safe 
in older patients, despite a higher 3-month mortality and a less 
favourable functional outcome. 13 
In this study we compared the safety and outcome of rtP A 
treatment in patients aged 80 years and older with their younger 
counterparts in a prospective cohort from the University Medical Center 
Groningen (UMCG). In contrast to most previous studies, we not only 
investigated the 3-month mortality but we also compared the early in­
hospital mortality at 7 days between the two groups. 
Methods 
UMCG Cohort 
After participation in the European Cooperative Acute Stroke Study 
(ECASS) II, our centre started with rtP A treatment for eligible stroke 
patients and served as referral centre for regional community hospitals. 
An ongoing prospective registry of patients treated with rtP A was started 
in April 2002. This study analysed the period between April 2002 and 
January 2006. Only the patients treated within 3 hours were selected for 
this study to compare out results with other cohorts. Inclusion and 
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exclusion criteria m this time window were based on those of the 
NINDS trial. 
Neurological deficit before start of rtPA treatment was assessed with 
the National Institute of Health Stroke Scale (NIHSS). All patients had a 
brain CT scan, blood investigation and electrocardiography. Baseline 
variables such as gender, age, vascular risk factors, serum glucose 
concentration, and antiplatelet medication were recorded. Stroke­
subtypes were defmed into lacunar infarcts (LACI) and non-lacunar 
infarcts (total anterior circulation infarcts (TACI) and partial anterior 
circulation infarcts (PACI)) according to the Oxfordshire Community 
Stroke Project Classification. 14  Patients were treated with intravenous 
rtP A according to the NINDS protocol. After treatment patients were 
monitored in a stroke unit, where early rehabilitation was started by a 
multidisciplinary team. We did not routinely perform a brain CT scan 
after each thrombolysis. 
For the safety analysis, we defmed the following outcome measures: 
incidence of symptomatic intracerebral haemorrhage (SICH), early in­
hospital mortality within 7 days and 3-month mortality. SICH was 
defined as a neurological deterioration (� 4 points on the NIHSS) within 
36 hours following thrombolysis with an intraparenchymal haematoma 
demonstrated by CT scan, which could explain the deterioration. 15  
Functional outcome was assessed after 3 months using the modified 
Rankin Scale (mRS). Good outcome was defined as mRS :S 1 and a 
functionally independent outcome as mRS :S 2. Data were analysed 
separately in the young and old age group and compared between both 
groups. 
Statistical analysis 
All statistical analyses were done using SPSS version 11.0. The Mann­
Whitney U and the independent samples T-test were used for 
continuous and ordinal variables, and the Pearson's X2 test or Fisher's 
exact test for dichotomous variables. Confidence intervals for 
proportions were calculated using Wilson's method. For the functional 
outcome and 3-month mortality a multivariate analysis was done to 
76 
Thrombofysis in the elderfy 
adjust for possible confounders: NIHSS score, time from onset until 
treatment, stroke subtype Q.acunar versus non lacunar) and blood glucose 
concentration. 
Results 
UMCG cohort baseline characteristics 
Between April 2002 and January 2006, 1,029 consecutive ischaemic 
stroke patients were admitted to our department, of whom 142 received 
rtP A treatment within 3 hours after onset. All patients were independent 
(mRS 0-2) before admission. Of the 142 treated patients 111 (78%) were 
younger than 80 years and 31 (22%) were 80 years or older. Baseline 
characteristics of both groups are summarised in the table. 
The median NIHSS tended to be higher in the older group (15 
versus 13), although this did not reach a statistical significant difference 
(p = 0.197). Older patients had a longer onset to treatment time (mean 
time 158 min versus 145 min in younger patients, p = 0.022) and were 
less likely to have a lacunar stroke (3% versus 19 % in the younger 
group, p = 0.046). 
Outcome 
SICH occurred in 4 of the younger patients (3.6%; 95% CI 1.4 - 8.9) of 
which 2 were fatal, and in 3 of the older patients (9.7%; 95% CI 3.3 -
24.9) of which 2 were fatal (p = 0.176). 
The in-hospital mortality at 7 days was 10.8% (95% CI 6.3 - 18.0, n 
= 12) in the younger group and 12.9% (95% CI 5.1 - 28.9, n = 4) in the 
older group (p = 0.751). 
After 3 months 12.6% (95 %CI 7.7 - 20.1, n = 14) of the younger 
patients had died compared with 45.2% (95% CI 29.2 - 62.2, n = 14) of 
the older patients (p<0.001). Of the 10 older patients who died after 7 
days and within 3 months, the cause of death was sequel to stroke (n = 
3), cardiopulmonary failure (n=5) and unknown (n=2). After adjustment 
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for confounders, age 2:: 80 years was independently associated with a 
higher mortality rate (OR 6.3; 95% CI 2.1 - 19.0). 
Table: Baseline characteristics 
<80 years 2:80 years 
Characteristics n = 111 n = 31 p 
Male 61  (55) 12 (39) 0.1101 
Age (y) 
mean ± SD 63.9 ± 13.0 83.6 ± 3.5 <0.0012 
median (range) 68 (29-79) 82 (80-91) 
NIHSS median (range) 13 (2-23) 15 (6-22) 0.1972 
OTT (min), mean ± SD 145.1 ± 30.7 157.8 ± 23.9 0.0222 
Lacunar stroke 21 (19) 1 (3) 0.0464 
EIC on CT 48 (43) 12 (38) 0.6511 
Systolic bloodpressure (mm Hg) 152 ± 24 159 ± 26 0. 1 953 
± SD 
Diastolic bloodpressure (mm Hg) 83 ± 13 79 ± 15 0.1253 
± SD 
Glucose level (mmol/1) ± SD 6.2 ± 1.5 6.4 ± 1.5 0.3692 
Vascular risk factors 
Atrial fibrillation 24 (21.6) 12 (38.7) 0.0531 
Hypertension 53 (48) 12 (39) 0.3721 
Diabetes 14 (13) 3 (10) 1.00 4 
H yperlipidaemia 31 (28) 5 (16) 0.1741 
Prior stroke 18  (1 6) 3 (10) 0.5674 
Current smoking 38 (34) 5 (1 6) 0.0901 
Prior use of antiplatelets 32 (29) 14 (45) 0.0861 
Values are numbers (%), unless otherwise indicated. OTT = onset to treatment time, 
EIC = early ischaemic changes, 1 Pearson's x2-test, 2 Mann-Whitney U-test, 3 
independent samples T-test, 4 Fisher's exact test 
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The distribution of the mRS scores 3 months after treatment is 
presented in the figure. Five patients aged 80 years or older (16.1 %; 95% 
CI 7.1 - 32.6) and 40 patients younger than 80 years (36.0%, 95% CI 
27.7 - 45.3) had a good outcome (p = 0.035). After adjustment for 
confounders, a non-significant trend towards unfavourable outcome 
(mRS > 1) was observed in the older patients (OR 2.6; 95% CI 0.8 -
8.7). 
Older patients had also less frequent a functionally independent 
outcome (7 /31 (23%) versus 57 /111 (51 %), p = 0.004). 
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Figure: Outcome on the modi_fted Rankin scale at three months 
Discussion 
The results of our study demonstrated that rtP A treatment in acute 
ischaemic stroke in patients aged 80 years or older, has a comparable 
safety profile with their younger counterparts. 
The overall incidence of SICH (4.9%) in our cohort was similar to 
that in other studies,6-1 1'1 6'17 the systematic review from Engelter et al18 
and in the NINDS study. 1 In line with previous studies, the mortality 
rate at 3 months was significantly higher in the group of 80 years or 
older.7-10 We also compared the early in-hospital mortality, which was not 
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different between the two groups. This means that the high mortality 
rate at 3 months is not related to acute stroke therapy, but to factors that 
occur after hospital discharge. Frail, vulnerable elderly who had a stroke 
have a higher prevalence of comorbidity and are more susceptible to 
complications and other illnesses than younger patients. The proportion 
of patients with a good or functionally independent outcome at 3 
months after rtP A treatment was significantly lower in the older patients, 
but is in line with the natural course of ischaemic stroke in this age 
group, demonstrated by other studies.19 Older patients may have had 
already a higher mRS score on admission, however, we did not 
thrombolyse any patient with significant pre-existent disability. In our 
cohort older patients had a longer onset to treatment time which could 
have confounded the outcome at 3 months. 
It is important to note that our and previous cohorts did not 
investigate the effectiveness of rtP A in the older patients. A randomised 
placebo controlled trial, the Third International Stroke Trial (IST-3), 
which also investigates the effectiveness of rtP A in patients older than 80 
. . years, 1s ongomg. 
Despite higher 3 month mortality and less favourable outcome in 
the very older patients treated with rtP A in acute stroke, the safety 
profile of treatment seems acceptable. At this moment efficacy data are 
lacking and therefore the decision to thrombolyse older stroke patients 
should be made on an individual basis. 
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Introduction - There is some uncertainty whether prior use of 
antiplatelet drugs (AP) increases the risk of symptomatic intracerebral 
haemorrhage (SICH) and influences functional outcome in patients with 
ischaemic stroke treated with intravenous thrombolysis. The aim of this 
study was to assess whether prior use of AP is related to outcome 
following intravenous recombinant tissue plasminogen activator (rtP A) 
therapy in patients with ischaemic stroke. 
Methods - We analysed the relation between prior AP therapy, 
occurrence of SICH and functional outcome of consecutive ischaemic 
stroke patients undergoing intravenous thrombolysis with rtP A in a 
university hospital between 2002 and 2006 in a single centre prospective 
observational cohort study. The endpoints were the occurrence of SICH 
and favourable outcome reflecting independence at 3 months defined as 
a modified Rankin Scale (mRS) score � 2. 
Results - Out of the 301 patients who received intravenous rtP A, 89 
used AP prior to thrombolysis. SICH occurred in 12 (13.5%; 95% CI 
7.8% - 22.3%) patients on AP and in 6 (2.8%; 1.2% - 6.2%) without 
prior AP therapy (p = 0.001). Multivariable analysis revealed that prior 
AP therapy was an independent predictor of SICH (odds ratio 6.0; 2.0 -
17.1). Nonetheless, prior AP therapy was independently associated with a 
favorable outcome (odds ratio 2.0; 1 .0 - 4.3). 
Conclusions - Despite a higher incidence of SICH, the net benefit of 
intravenous rtP A for acute ischaemic stroke may be greater in patients 
using AP drugs. 
84 
Antzplatelet therapy before thrombo/ysis 
Introduction 
Intravenous thrombolysis with recombinant tissue plasminogen activator 
(rtP A) improves outcome in a selected group of acute ischaemic stroke 
patients, but is associated with a tenfold increased risk of symptomatic 
intracerebral haemorrhage (SICH). 1 It is critical to select those patients 
who are likely to benefit from rtP A treatment without having an 
increased risk of SICH. Antiplatelet (AP) therapy impairs thrombocyte 
function and might increase the risk of a bleeding complication after 
intravenous thrombolysis. 
In the guidelines of the American Heart Association (AHA), prior 
AP use is no contraindication for rtPA treatment,2'3 although starting AP 
therapy within 24 hours after rtP A treatment is discouraged. 2 
The question whether rtP A treatment is safe in patients receiving AP 
therapy merits further investigation since a number of patients with acute 
ischaemic stroke have a history of previous vascular events4 and receive 
AP therapy at the time of the ischaemic stroke. 
In this study we compared the incidence of SICH and 3 month 
functional outcome following intravenous thrombolysis between patients 
with and without prior AP therapy. 
Methods 
Patients 
All consecutive patients with ischaemic stroke receiving rtP A treatment 
at the University Medical Center Groningen (UMCG) stroke care unit 
were included in a prospective registry starting in April 2002. For this 
study, we analysed data acquired until November 2006. In- and exclusion 
criteria for rtP A treatment within 3 hours were adopted from the 
National Institute of Neurological Disorders and Stroke (NINDS) trial 
protocol. 1 On the basis of the pooled analysis from the three large rtP A 
randomised placebo-controlled trials,5 we offered t-PA treatment to 
patients up to 4.5 hours following stroke onset, after explaining the 
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unlicensed use and after obtaining informed consent.6 For patients 
treated between 3 and 4.5 hours we used the European Cooperative 
Acute Stroke Study (ECASS) II protocol.7 Inclusion was extended to 
patients older than 80 years. We performed a subgroup analysis on 
patients treated within 3 hours following stroke onset. 
Neurological deficit was measured with the National Institute of 
Health Stroke Scale (NIHSS). All patients underwent a brain CT scan, 
blood investigations and electrocardiography before rtP A treatment. We 
did not routinely perform post-treatment brain CT scans. Stroke subtype 
was classified as: total anterior circulation infarction (TACI), partial 
anterior circulation infarction (PACI), lacunar infarction (LACI) and 
posterior circulation infarction (PACI) according to the Oxfordshire 
Community Stroke Project.8 Demographics, vascular risk factors, glucose 
concentration and prior AP use were recorded in the registry. AP use 
and dosage was documented at admission in the clinical record file. Early 
ischaemic changes on brain CT scan were defined as effacement of 
cerebral sulci, loss of gray /white matter differentiation, and parenchymal 
hypodensity. All brain CT scans were reassessed with the investigator 
blinded for patient outcome. 
Outcome measures 
The incidence of SICH was compared between patients with and 
without AP therapy before rtP A treatment. SICH was defined as a 
neurological deterioration (NIHSS 2: 4 points) within 36 hours and a 
parenchymal hematoma on brain CT in a location compatible with the 
clinical symptoms, according to the Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOST) definition.9 
The modified Rankin Scale (mRS) was used to determine functional 
outcome at 3 months. Favorable outcome was defined as a mRS score ::S 
2, corresponding to independence with regard to activities of daily 
li · 10 vmg. 
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AP and risk of SICH 
Patients with prior AP therapy are likely to be older and have a higher 
prevalence of vascular risk factors and more previous vascular events. 
These imbalances in patient characteristics may confound the relation 
between AP and SICH. To investigate whether prior AP was 
independently associated with SICH, we assessed differences in baseline 
characteristics between patients with and without prior AP therapy and 
variables with a p-value < 0.2 were selected as covariates for the 
multivariable analysis. Serum glucose level, age, early ischaemic changes 
on initial brain CT scan and higher NIHSS scores were also entered in 
the multivariable model, regardless of the univariate analysis, since these 
variables have previously been associated with an increased risk of 
SICH.11'1 2  In the final logistic regression model with SICH as dependent 
variable, adjusted variables with a p-value > 0.2 were removed. 
AP and functional outcome 
The same approach was used to investigate whether prior AP therapy 
was independently associated with favorable outcome. Variables that 
were different between patients with and without prior AP (with a p­
value < 0.2) were selected as covariates for the multivariable analysis. 
The following covariates were also considered to be possible 
confounders and were entered in the multivariable analysis, regardless of 
the univariate analysis: age, NIHSS score, serum glucose levels, gender, 
stroke subtype (lacunar versus non-lacunar), onset to treatment time, 
occurrence of SICH and early ischaemic changes on brain CT scan. In 
the final logistic regression model with favorable outcome as dependent 




Fisher's exact tests, Pearson's chi square tests and the Mann-Whitney-U­
tests were used for comparisons of the baseline characteristics and 
univariate analyses, where appropriate. Multivariable analyses were done 
using logistic regression models. Goodness of fit of all regression models 
was assessed with the Hosmer Lemeshow statistic.13 Statistical 
significance was taken to be at the two-tailed 0.05 level. All statistical 
analyses were performed with the Statistical Package for the Social 
Sciences (SPSS 14.0 for Windows, Chicago, Illinois). 
Results 
UMCG rtPA registry 
Of the 301 patients with ischaemic stroke receiving rtP A treatment, 89 
(30%) were on AP therapy. One hundred eighty-eight (63%) patients 
were treated within 3 hours of stroke onset. Baseline characteristics of 
patients with and without AP therapy are presented in table 1. As 
expected, AP pre-treated patients were older and more frequently had a 
history of previous arterial hypertension, diabetes mellitus, 
hyperlipidaemia and previous stroke. 
AP treatment consisted of aspirin 1n 66 (73%) patients, the 
combination aspirin-dipyridamole 1n 22 (25%), dipyridamole 
monotherapy in 1 (1 % ) and clopidogrel monotherapy in 1 (1 % ) . 
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Table 1: Baseline characteristics of patients with and without prior AP 
Prior AP therapy No prior AP therapy 
Characteristic n = 89 n = 212 p 
Mean age (SD), y 73 (11) 66 (15) <0.001· 
Male 46 (52) 112 (53) 0.86 
Median NIHSS score (range) 12 (2-35) 13 (2-25) 0.26* 
Median time until treatment 165 (30-270) 175 (70-285) 0.43* (range), min 
Stroke-subtypet 0.72 
TACI 26 (29) 76 (36) 
PACI 44 (49) 95 (45) 
LACI 16 (18) 33 (16) 
POCI 3 (3) 7 (3) 
Mean systolic blood pressure 158 (26) 152 (28) 0.06* (SD), mm Hg 
Mean diastolic blood pressure 83 (14) 83 (17) 0.84. (SD), mm Hg 
Mean glucose level (SD), 6.4 (2.0) 6.4 (1.9) 0.66* mmol/1 
Early ischaemic changes on 34 (38) 92 (44) 0.39 brain CT scant 
Vascular risk factors 
Hypertension 52 (58) 82 (39) 0.002 
Diabetes 17 (19) 19 (9) 0.01 
H yperlipidaemia§ 43 (48) 48 (23) <0.001 
Atrial fibrillation 22 (25) 54 (26) 0.89 
Smoking !! 20 (24) 70 (37) 0.03 
Previous stroke / TIA 41 (46) 11 (5) <0.001 
Values are presented as number (%) and p-values calculated with Fisher's exact tests, 
unless otherwise indicated. * Mann-Whitney-U-Test. NIHSS: NIH stroke scale. TACI / 
PACI / LACI / POCI: total / partial anterior circulation / lacunar / posterior 
circulation infarction. tl missing values in no prior AP group, +1 missing in no prior AP 
group, §6 missing in no prior AP group, 11 26 missing values ( 4 in prior AP group, 22 in 




In the overall group (treated between 0 and 4.5 hours), SICH occurred in 
1 8  patients (6.0%; 95% confidence interval 3.8 - 9.3) of whom 12  
( 13.5%; 7.8 - 22.3) were on prior AP therapy and 6 (2.8%; 1 .2 - 6.2) 
were not (p = 0.003). The absolute risk difference of approximately 1 0%, 
translates into one additional SICH in every tenth thrombolysed patient 
with prior AP therapy. 
Ten of the 12  patients with SICH used aspirin in a dose of 30-50 mg 
(2 patients), 80-100 mg (7 patients) and an unknown dose in 1 patient. 
Two patients used the combination aspirin-dipyridamole (in a dose of 
25/200 mg). There were 9 SICH in 62 patients pre-treated with aspirin 
(1 4.5%; 7.7 - 25.7) versus 9 SICH in 239 patients in the non-aspirin 
group (3.8%; 1 .9 - 7.1 ), p = 0.004. 
When excluding patients who received rtP A beyond 3 hours of 
stroke onset, there were 9 SICH in 60 patients with prior AP therapy 
(1 5.0 %; 7.9 - 26.4) versus 3 in 1 28 patients without prior AP therapy 
(2.3%; 0.5 - 7.0), p = 0.002. In the group treated between 3 and 4.5 
hours, there were 3 SICH in 29 patients with prior AP therapy (5.3%; 2.9 
- 27.4) versus 3 in 84 patients without prior AP (3.6%; 0.8 - 1 0.5), p = 
0.1 8. 
In the final regression model (table 2), prior AP therapy was an 
independent predictor of SICH in the total cohort ( odds ratio 6.0; 2.0 -
17  .1 ) together with higher serum glucose and higher NIHSS score. In the 
subgroup analysis of patients treated within 3 hours, prior AP therapy 
remained an independent predictor (odds ratio 1 0.9; 2.4 - 49.3), together 
with higher serum glucose level. 
Forty-five (51 %) of the 89 patients with and 95 (45%) of the 212 
patients without prior AP therapy had a favorable outcome (mRS 0-2) (p 
= 0.38). In the final logistic regression analysis (table 3) with adjustment 
for age, NIHSS, systolic blood pressure, diabetes, history of 
hypertension, occurrence of SICH, and presence of early ischaemic 
changes, AP therapy was associated with favorable outcome ( odds ratio 
2.0; 1 .0 - 4.3). In the subgroup treated within 3 hours a non-significant 
trend toward an association of AP with favorable outcome was observed 
(table 3). 
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Table 2: Final logistic regression model for prediction of SICH 
Entire cohort Cohort treated within 3 
(n=301) hours (n=1 88) 
Variables OR 95% CI p OR 95% CI p 
AP therapy 5.96 2.01 - 1 7.1 0.001 10.9 2.40 - 49.3 0.002 
NIHSS score* 1 . 12  1 .02 - 1 .22 0.01 1 . 12  0.97 - 1 .28 0.12 
Glucose, mmol/L * 1 .25 1 .02 - 1 .54 0.04 1 .63 1 . 1 6 - 2.29 0.005 
* for each 1 point (NIHSS) and 1 mmol/L (glucose) increase. The following variables 
were tested: AP therapy, age, NIHSS score, early ischaemic changes, serum glucose, 
systolic blood pressure, hypertension, diabetes mellitus, hyperlipidaemia, smoking, 
previous stroke/TIA. Variables with an adjusted p-value > 0.2 were removed. Hosmer 
Lemeshow test: p = 0.50 / 0.45 
Table 3: Final logistic regression model with predictors of favourable 
outcome 
Entire cohort Cohort treated within 3 hours 
(n=301) (n= 188) 
Variables OR 95% CI p OR 95% CI p 
AP therapy 2.01 1 .03 - 4.26 0.04 2.44 0.97 - 6. 1 1  0.06 
Age, y* 0.93 0.91 - 0.96 <0.001 0.92 0.88 - 0.95 <0.001 
NIHSS score * 0.82 0.76 - 0.87 <0.001 0.81 0.74 - 0.89 <0.001 
Early ischaemic 0.58 0.31 - 1 . 1 1  0 .10 0.34 0 .14 - 0.82 0.02 changes on CT 
Systolic blood 1 .01 1 .00 - 1 .02 0.02 1 .02 1 .00 - 1 .04 0.02 pressure 
Hypertension 0.44 0.23 - 0.84 0.01 0.56 0.24 - 1 .31 0.18 
Diabetes 0.51 0 .18 - 1 .43 0.20 
SICH 0.22 0.05 - 0.95 0.04 
* for each 1 year, 1 point and 1 mm Hg increase. The following variables were tested: 
AP therapy, age, NIHSS score, early ischaemic changes, serum glucose, systolic blood 
pressure, hypertension, diabetes mellitus, SICH, hyperlipidaemia, smoking, previous 
stroke/TIA, stroke subtype, gender and onset to treatment time. Variables with 




This study demonstrates that patients receiving AP therapy have a 
substantially higher risk of SICH after rtPA treatment than patients 
without prior AP therapy. Despite this increased risk, prior AP therapy 
net increased the odds of a favourable outcome. Therefore our study 
suggests that rtP A treatment should not be withheld from patients 
receiving AP therapy. 
Acute ischaemia may lead to endothelial injury and disruption of the 
blood brain barrier. AP may further predispose to SICH after rtP A 
treatment by impairing platelet aggregation. Previous studies reported 
conflicting results about the safety of AP use prior to intravenous 
thrombolysis. One study that investigated the relation between aspirin 
pre-treatment and SICH following intravenous rtP A found no 
association with intracerebral haemorrhage. 12 In the Multicenter rtP A 
Acute Stroke Survey,13 patients on aspirin were at higher risk for SICH in 
the univariate analysis, whereas in the multivariate analysis AP other than 
aspirin were predictive of SICH. A re-analysis of the European 
Cooperative Acute Stroke Study (ECASS) II showed that the risk of 
parenchymal haemorrhage was increased in aspirin pre-treated patients 
who received rtP A, but not in the aspirin pre-treated patients who 
received placebo.14 In the NINDS study, prior aspirin treatment was not 
associated with SICH. 1 5  The discrepancies between some of these 
previous studies and our study may be explained by different dosage of 
AP, or the use of other AP than aspirin. In our study, however, aspirin 
monotherapy was also associated with SICH. 
Consistent with previous findings, higher NIHSS scores and higher 
glucose levels were also found to predict SICH in our cohort.13'1 5'1 6  
A meta-analysis showed that prior use of antithrombotics does not 
improve functional outcome in ischaemic stroke patients not treated 
with rtP A. 17 Little is known about the effect of AP therapy before rtP A 
treatment on functional outcome. 
We found, that despite the increased risk of SICH, prior AP therapy 
was associated with a favourable outcome. A possible mechanism behind 
this beneficial effect is that aspirin remains biologically active for four to 
six days and might prevent early reocclusion after rtP A treatment. A 
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previous study showed that patients using aspirin before rtP A treatment 
developed early clinical deterioration less frequently than patients 
without aspirin. 1 8  
In our study, no association was found between prior AP therapy 
and outcome of rtP A treatment in univariate analysis. This confirms the 
subgroup analysis of the NINDS trial which did not find any effect of 
aspirin on clinical outcome in univariate models. 19 However, both 
outcome and prior AP therapy are known to be related to age, 
hypertension, and prior vascular events.20 Timing of rtPA treatment may 
alter the relation between prior AP therapy and outcome. Consequently, 
confounding needs to be adjusted for in a multivariable analysis. In our 
cohort, the multivariable analysis showed an association of prior AP 
therapy with favourable outcome. 
Our study has limitations. First, we did not perform routine brain 
CT scans after rtP A treatment, and therefore we have no information on 
the effect of prior AP therapy on the development of asymptomatic 
haemorrhagic transformation. Second, the incidence of SICH in our 
study was low. On the other hand, even in a relative small sample size, 
the relation between SICH and AP was highly significant in both 
univariate and multivariate analyses. Although we treated patients up to 
4.5 hours after stroke onset, the subgroup analysis of the patients treated 
within 3 hours revealed no important differences compared to the 
analyses of the entire cohort regarding the risk of SICH and the chance 
of a favourable outcome. Among the patients treated between 3 and 4.5 
hours, the incidence of SICH was not significant higher in patients with 
prior AP, but this may be explained by the low patient numbers in this 
group. 
In summary, prior AP therapy before IV thrombolysis is associated 
with an increased risk of SICH, but was also independently associated 
with a favourable outcome. Larger prospective studies are warranted to 
further investigate the influence of AP on outcome after thrombolytic 
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Background - Low cholesterol levels have been associated with an 
increased risk of haemorrhagic stroke . This study investigated whether 
lipid levels or prior statin use influence outcome in patients with acute 
ischaemic stroke treated with intravenous (IV) recombinant tissue 
plasminogen activator (rtPA). 
Methods - The relation between admission lipid levels or statin use and 
both the development of symptomatic intracerebral haemorrhage (SICH) 
and 3-months functional outcome was assessed in a prospective hospital­
based stroke registry comprising 252 patients treated with IV rtP A. 
Favourable outcome at 3 months was defined as a modified Rankin scale 
score ::S 2. Logistic regression analysis was performed with adjustment 
for possible confounders. 
Results - Low density lipoprotein (LDL), high density lipoprotein 
(HDL), total cholesterol levels, and statin use, were not associated with 
SICH. Mean triglyceride levels were significantly higher (2.5 mmol/L vs 
1 .8 mmol/L, p=0.02) and high density lipoprotein (HDL) were 
significantly lower (1 .0 mmol/L vs 1 .2 mmol/L, p=0.03) in patients with 
sICH than in patients without sICH. Multivariable analysis showed that 
higher triglyceride levels were independently associated with SICH (OR 
2.08 per mmol/L increase, 95% CI 1 . 14  - 3.79, p=0.02). There was no 
relation between any of the lipid levels and functional outcome at 3 
months. 
Conclusions - High admission triglyceride levels were associated with a 
higher rate of SICH, but triglyceride levels did not influence functional 
outcome at 3 months. Cholesterol levels or statin use had no influence 
on both the occurrence of SICH or functional outcome. 
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Introduction 
Intravenous (IV) thrombolysis with recombinant tissue plasminogen 
activator (rtP A) has been shown to improve clinical outcome in a 
selected group of ischaemic stroke patients. 1 '2 The most feared 
complication of this therapy is the occurrence of a symptomatic 
intracerebral haemorrhage (SICH).2 It is therefore important to 
investigate which patients are likely to benefit from this treatment and 
which patients are at high risk for complications. Predictors of SICH 
have been investigated since the introduction of tP A therapy3-5 and 
randomised controlled trials are still ongoing to further investigate which 
patients are most likely to benefit. 
A number of epidemiological studies showed an association of low 
cholesterol levels, statin use and increased risk of haemorrhagic stroke, G-s 
and this observation was corroborated in the Stroke Prevention by 
Aggressive Reduction in Cholesterol Levels (SP ARCL) study. 9 Since 
statins are widely used in the primary and secondary prevention of 
cardiovascular diseases, the number of patients on statin therapy 
presenting with acute ischaemic stroke is likely to increase. 
A small retrospective study found an association between low­
density lipoprotein cholesterol (LDL) and symptomatic haemorrhagic 
transformation in a mixed population of patients undergoing IV 
thrombolysis, intra-arterial thrombolysis or mechanical embolectomy. 10  
The purpose of this study was to investigate whether lipid profile 
and statin use are associated with SICH and influence functional 
outcome in a cohort of consecutive patients with acute ischaemic stroke 





Data of consecutive ischaemic stroke patients receiving rtP A were 
collected from April 2002 until October 2006. In our centre, patients 
were treated up to 4.5 hours of stroke onset and this protocol has been 
described previously. 1 1  We used the inclusion and exclusion criteria of 
the National Institute of Neurological Disorders and Stroke study1 for 
patients treated within 3 hours of stroke onset. For the patients who 
were treated off-label in the 3 to 4.5 hours time window, we used the 
inclusion and exclusion of the European Cooperative Acute Stroke 
Study II, 12 except for the upper age limit of 80 years. Initial stroke 
severity was assessed with the National Institute of Health Stroke Scale 
(NIHSS). Stroke subtype was defined according to the Oxfordshire 
Community Stroke Project and classified as total or partial anterior 
circulation infarction (TACI, PACI), lacunar infarction (LACI) or 
posterior circulation infarction (POCI) .13 Demographics, vascular risk 
factors, blood pressure and time from onset until treatment were 
recorded. All patients underwent a non-contrast brain CT scan before 
treatment, but no routine brain CT scan was made after thrombolysis. 
Admission (non-fasting) serum glucose levels, total cholesterol, high 
density lipoprotein cholesterol (HDL), low density lipoprotein 
cholesterol (LDL) and triglyceride concentrations were determined by 
commercial methods (Merck Mega, Darmstadt, Germany and Roche 
Modular, Mannheim, Germany). Lipid levels were determined in the 
acute phase, approximately 30 minutes before start of tP A 
administration. No information about fasting status was obtained. 
Outcome 
SICH was defined as a neurological deterioration (NIHSS � 4 points) 
within 36 hours following rtP A treatment with a parenchymal 
haematoma on brain CT scan compatible with the clinical symptoms. 14  
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Functional outcome at 3 months was assessed with the modified Rankin 
scale (mRS). 15 A favourable outcome was defined as a mRS ::; 2. 
Statistical analysis 
U nivanate ana!Jses 
For dichotomous variables, group comparisons were performed using 
the Fisher's exact test. The distribution of lipid levels was assessed with 
the Kolmogorov-Smirnov test and the Mann-Whitney-U test was used 
for ordinal and continuous data for group comparisons. 
Multivariab/e ana!Jses 
The effect of lipid levels or statin use on SICH was assessed with logistic 
regression models with adjustment for possible confounders: age, 
NIHSS, early ischaemic changes on initial brain CT scan, treatment 
beyond 3 hours, serum glucose concentration, history of arterial 
hypertension, diabetes mellitus and use of antiplatelets. Since HDL and 
LDL are highly correlated with total cholesterol, only total cholesterol 
and triglycerides were entered into the regression model as continuous 
variables. In addition we also separately entered LDL and HDL in the 
regression model Interaction terms between cholesterol, triglycerides, 
serum glucose level, and statin use, were also included and removed 
from the model if not statistically significant. 
The same approach was used for assessing the relation between lipid 
levels or statin use and functional outcome. In this model the following 
covariates were entered: age, NIHSS, early ischaemic changes on initial 
brain CT scan, treatment beyond 3 hours, serum glucose concentration, 
occurrence of SICH, non-lacunar stroke and use of antiplatelets. 
The goodness of fit of the regression models was calculated with the 
Hosmer-Lemeshow statistic. Statistical significance was taken to be at 
the two-tailed 0.05 level. All statistical analyses were performed with the 






A total of 301 patients were treated with rtP A. In this group, data about 
at least one of the lipids were missing in 49 patients, leaving 252 patients 
for further analysis. Baseline characteristics are presented in table 1. 
Glucose, HDL and triglyceride levels did not follow a normal 
distribution. Mean serum total cholesterol and LDL levels were 
significantly lower (p<0.001) among patients using statins. 
Symptomatic intracerebral haemorrhage 
SICH occurred in 13 patients (5.2%, 95% confidence interval 3.0 - 8.7). 
Patients with SICH more frequently used antiplatelets before rtP A 
treatment and had higher serum triglyceride concentrations and lower 
HDL levels (table 1) (table 1, figure). There was no difference in SICH 
rate between statin users and nonusers and cholesterol levels were not 













































Figure: Boxplots showing the distribution of lipid levels in patients with and without 
SI CH) and with and without favourable outcome. 
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Table 1: Baseline characteristics I Q 
Total (n=252) SICH (n= 13) No SICH (n=239) 1 �  Mean age (SD), years 68 (1 5) 73 (9) 68 (1 5) 
Male 136 (54) 8 (62) 128 (54) 
Median NIHSS score [IQR] 12  [8-17] 14 [9-21] 12 [8-17] 
Median time until treatment [IQR] , min 174 [139-210] 1 80 [1 50-195] 1 72 [135-210] 
Treatment within 3 hours of stroke onset 1 58 (63) 10 (77) 148 (62) 
Stroke-subtype§ 
TACI 89 (36) 7 (54) 82 (35) ..p,... 
PACI 1 1 8  (47) 4 (31) 1 1 4  (48) 
LACI 38 (15) 2 (1 5) 36 (1 5) 
POCI 6 (2) 6 (3) 
Mean systolic blood pressure (SD), mm Hg 1 54 (27) 1 64 (25) 153 (27) 
Mean diastolic blood pressure (SD), mm Hg 84 (16) 89 (14) 84 (16) 
Mean glucose level (SD), mmol/L 6.4 (1 .9) 6.9 (2.3) 6.4 (1 .9) 
Mean total cholesterol level (SD), mmol/L 5.1 (1 .2) 5 .1  (1 .2) 5 .1  (1 .2) 




Table 1: Continued 
Total (n=252) SICH (n= 13) No SICH (n=239) 
Mean LDL level (SD), mmol/L 3.1 (1.0) 3.0 (0.8) 3. 1 (1 .0) 
Mean triglyceride level (SD), mmol/L 1 .9 (1 .1) 2.5 (1.7)** 1 .8 (1 .1)** 
Early ischaemic changes on brain CT scan 107 (43) 7 (54) 100 (42) 
Vascular risk factors 
History of arterial hypertension 1 1 1  (44) 6 (46) 105 (44) 
Diabetes mellitus 29 (12) 2 (1 5) 27 (1 1) 
Hyperlipidaemia 78 (31) 5 (39) 73 (31) 
Atrial fibrillation 64 (25) 4 (31) 60 (25) 
Current smokert 76 (33) 3 (23) 73 (34) 
Previous stroke 39 (16) 2 (15) 37 (16) 
Prior use of antiplatelets 71 (28) 9 (69)# 62 (26)# 
Prior use of statinst 39 (16) 3 (25) 36 (1 5) 
Values are numbers (%), unless otherwise indicated. * p =0.03, ** p=0.02, # p=0.002, p-values not adjusted for 
multiple comparisons. § 1 missing value (in no SICH group), t 10 missing values (all in no SICH group), :t: 6 missing 
values (1 in SICH group). SICH = symptomatic intracerebral haemorrhage, SD = standard deviation, IQR = 
interquartile range, HDL = high density lipoprotein, LDL = low density lipoprotein, NIHSS: NIH stroke scale, TACI 
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In the multivariable model (table 2), triglycerides were associated 
with SICH (odds ratio 2.08, 95% confidence interval 1.14 - 3.79, p = 
0.02). Prior antiplatelet therapy was also associated with SICH. 
Interaction terms between cholesterol, triglycerides, serum glucose level, 
and statin use were not significant. Neither LDL levels nor HDL levels 
were independently associated with sICH, when these lipid levels were 
separately entered in the logistic regression model instead of total 
cholesterol. 
Table 2: Multivariable analysis: association of lipid levels and statins 
with SICH 
Odds ratio 95% confidence P value interval 
Total cholesterol, per mmol/1 increase 0.77 0.42 - 1.42 0.41 
Triglycerides, per mmol/1 increase 2.08 1.14 - 3.79 0.02 
Age, per year increase 1.02 0.96 - 1.09 0.54 
NIHSS per point increase 1.17 0.99 - 1.38 0.06 
Onset to treatment time > 3 hours 0.50 0.09 - 2.81 0.43 
Serum glucose level, per mmol/1 1.36 0.96 - 1.92 0.08 increase 
History of arterial hypertension 0.50 0.13 - 1.98 0.33 
Diabetes mellitus 0.39 0.05 - 2.88 0.36 
Starin use 0.90 0.17 - 4.78 0.90 
Antiplatelet use 8.09 1.55 - 42.1 0.01 
Early ischaemic changes on brain CT 0.70 0.14 - 3.54 0.66 
Hosmer-Lemeshow p = 0.95. SICH = symptomatic intracerebral haemorrhage, NIHSS 
= NIH stroke scale. 
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Functional outcome 
At 3 months, 122 patients (49%) had a favourable functional outcome. 
The distribution of the lipid levels was not significantly different between 
patients with a favourable and unfavourable outcome (figure). The 
number of patients with a favourable outcome was not different between 
users and non-users of statins (46% versus 50%, p = 0.73). In a 
multivariable analysis, with adjustment for confounders, lipid levels or 
statin use were not associated with a favourable outcome (table 3). 
Lower NIHSS scores, younger age, use of antiplatelets and absence of 
early ischaemic changes on brain CT scan were associated with a 
favourable outcome. 
Table 3: Multivariable analysis: association of lipid levels and statins 
with favourable outcome 
Odds ratio 95% confidence P value interval 
Total cholesterol, per mmol/1 increase 1.20 0.86 - 1.66 0.28 
Triglycerides, per mmol/1 increase 0.89 0.61 - 1.29 0.53 
Age, per year increase 0.93 0.90 - 0.96 <0.001 
NIHSS per point increase 0.84 0.78 - 0.91 <0.001 
Onset to treatment time > 3 hours 1.25 0.61 - 2.59 0.54 
Serum glucose level, per mmol/1 1.02 0.86 - 1.21 0.83 increase 
Early ischaemic changes on brain CT 0.36 0.17 - 0.76 0.007 
Occurrence of SICH 0.41 0.07 - 2.25 0.30 
Starin use 0.70 0.25 - 1.94 0.50 
Antiplatelet use 2.49 1.09 - 5.70 0.03 
Non-lacunar stroke 0.92 1.32 - 2.62 0.88 
Hosmer-Lemeshow p = 0.45. SICH = symptomatic intracerebral haemorrhage, NIHSS 




Admission total serum cholesterol, LDL or HDL levels and prior statin 
use were not independently associated with the occurrence of SICH or 
an unfavourable outcome. In contrast, we found an association between 
higher serum triglyceride levels and the occurrence of SICH. However, 
despite this increased risk, higher triglyceride levels were not associated 
with a reduced chance of favourable functional outcome at 3 months. 
Our results do not confirm the findings of a previous study which 
found that low LDL levels were associated with SICH.10 This may be 
due to differences in study design. In our study all patients received IV 
rtP A. In the previous study only 26 (25%) patients were treated with IV 
rtP A alone, of whom 3 developed SICH. The remainder of the patients 
(n = 79) underwent intra-arterial recanalisation therapies and the number 
of SICH (n = 14) was higher in these patients. Another single centre 
study found that patients using statins before rtP A treatment had more 
often a better outcome than patients without statin therapy.16 
We do not have a clear explanation how higher serum levels of 
triglycerides could enhance the risk of cerebral haemorrhage following 
thrombolysis. Very little work has been performed in this area. In a large 
population based case-control study, higher serum triglyceride levels 
were found to be an independent risk factor for primary intracerebral 
haemorrhage.17 The investigators did not find any relationship between 
cholesterol levels and the incidence of primary intracerebral 
haemorrhage. A systematic review suggested that higher serum 
cholesterol levels were associated with a lower incidence of primary 
intracerebal haemorrhage, but the role of triglycerides was not assessed.18 
A possible mechanism underlying the higher risk of SICH is that high 
triglyceride levels may predispose to endothelial injury, 19 which could 
lead to a subsequent blood-brain barrier disruption. 
A number of other variables were previously found to be associated 
with SICH, including a low platelet count, higher NIHSS score, 
hyperglycaemia and diabetes mellitus.4•20 Hyperglycaemia can lead to 
endothelial injury and subsequent intracerebral haemorrhage, especially 
in case of successful reperfusion.21 Matrix metalloproteinase-9 (MMP-9), 
an enzyme that can degrade basal lamina proteins, may play a key role in 
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the pathophysiology of endothelial injury and raised MMP-9 levels are 
related with SICH.22-24 Interestingly, statins have been shown to reduce 
rtP A induced MMP-9 production.25 
Our study has a number of limitations. First, the number of SICH 
was low, which limits the performance of the regression models. Second, 
we did not routinely perform post-treatment brain CT scans, and 
therefore we have no information on asymptomatic haemorrhagic 
transformation. Third, patients with diabetes mellitus more often have 
higher triglyceride levels,26 and both diabetes and hyperglycaemia are 
associated with SICH. Although we adjusted for both variables in a 
logistic regression analysis (including interaction terms), we cannot 
exclude possible confounding. 
In summary, low total cholesterol, LDL levels and statin use were 
not associated with sICH or unfavourable outcome. Higher TG levels in 
our study group were associated with a higher risk of SICH, but not with 
unfavourable functional outcome at 3 months. The clinical relevance of 
our findings requires further investigation. 
References 
1 .  Tissue plasminogen activator for acute ischemic stroke. The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1 995; 
333(24):1 581-1587. 
2. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute 
ischaemic stroke. Cochrane Database Syst Rev 2003;(3):CD000213. 
3. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR. 
Predictors of good outcome after intravenous tP A for acute ischemic stroke. 
Neurology 2001;  57(3):474-480. 
4. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, 
Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous 
recombinant tissue plasminogen activator therapy f�j acute ischemic stroke in clinical practice The multicenter rt-PA acute strof e survey. Circulation 2002; 105(14) :1679-1685. 
5. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, 
Heidrich J, Hermanek P, Leffmann C, Sitzer M, Biegler M, Buecker-Nott HJ, 
109 
Chapter 8 
Berger K. Predictors of in-hospital mortality in patients with acute ischemic stroke 
treated with thrombolytic therapy. JAMA 2004; 292(15): 1831-1838. 
6 .  Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Jr., Psaty 
BM. Association of cholesterol with stroke risk varies in stroke subtypes and 
patient subgroups. Neurology 2004; 63(10):1868-1875. 
7. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and 
Coronary Heart Disease Collaborative Research Group. Lancet 1998; 
352(9143):1801-1807. 
8. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey SG. Serum 
cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: 
Korean national health system prospective cohort study. BM] 2006; 333(7557):22. 
9. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, 
Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose 
atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 
355(6):549-559. 
10. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck 
B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B. 
Cholesterol level and symptomatic hemorrhagic transformation after ischemic 
stroke thrombolysis. Neurology 2007; 68(10):737-742. 
11. Uyttenboogaart M, Vroomen PC, Stewart RE, De Keyser J, Luijckx GJ. Safety of 
routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 
2007; 254(1-2):28-32. 
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, 
Bluhmki E, Davis S, Donnan G. Randomised double-blind placebo-controlled trial 
of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke 
(ECASS II). Lancet 1998; 352(9136):1245-1251. 
13. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural 
history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 
337 (8756):1521-1526. 
14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grand M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Raine RO, Soinne L, Toni D, 
Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe 
Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an 
observational study. Lancet 2007; 369(9558):275-282. 
15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver 
agreement for the assessment of handicap in stroke patients. Stroke 1988; 19(5):604-607. 
1 1 0  
Lipid profile, statin use and thrombo/ysis 
16. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, Molina 
CA, Montaner J. Prior statin use may be associated with improved stroke outcome 
after tissue plasminogen activator. Stroke 2007; 38(3):1076-1078. 
17. Zia E, Pessah-Rasmussen H, Khan FA, Norrving B, Janzon L, Berglund G, 
Engstrom G. Risk factors for primary intracerebral hemorrhage: a population­
based nested case-control study. Cerebrovasc Dis 2006; 21(1-2):18-25. 
18. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34(8):2060-
2065. 
19. Ferreira AC, Peter AA, Mendez AJ, Jimenez JJ, Mauro LM, Chirinos JA, Ghany R, 
Virani S, Garcia S, Horstman LL, Purow J, Jy W, Ahn YS, de ME. Postprandial 
hypertriglyceridemia increases circulating levels of endothelial cell microparticles. 
Circulation 2004; 110(23) :3599-3603. 
20. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The 
NINDS t-PA Stroke Study Group. Stroke 1997; 28(11):2109-2118. 
21. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina 
A, Quintana M. Effects of admission hyperglycemia on stroke outcome in 
reperfused tissue plasminogen activator-treated patients. Stroke 2003; 34(5):1235-
1240. 
22. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces 
thrombolytic (tissue plasminogen activator)-induced hemorrhage after 
thromboembolic stroke. Stroke 2000; 31(12):3034-3040. 
23. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A. 
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in 
acute ischemic stroke. Stroke 2003; 34(1):40-46. 
24. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana 
M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts 
intracranial hemorrhagic complications after thrombolysis in human stroke. 
Circulation 2003; 107(4):598-603. 
25. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, Lo EH. Reduction of 
tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in 
astrocytes. Stroke 2006; 37(7):1910-1912. 
26. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular 
risk factors in confirmed prediabetic individuals. Does the clock for coronary heart 
disease start ticking before the onset of clinical diabetes? JAMA 1990; 
263(21):2893-2898. 
1 1 1  

CHAPTER 9 
External validation of the stroke­
thrombolytic predictive instrument in 
daily clinical practice 
Maarten Uyttenboogaart, 1 R(!Y E. Stewart/ Patrick CA.]. Vroomen, 1 Jacques De 
Kryser, 1 Gert-] an Luijckx 1 
From the Departments of Neurology1 and Health Sciences2, University 
Medical Center Groningen, Groningen, The Netherlands 




Background - The stroke thrombolytic predictive instrument (s-TPI) 
has been developed to predict outcome after intravenous treatment with 
recombinant tissue plasminogen activator (rtP A) for acute ischaemic 
stroke. The aim of this study was to assess the external validity of the s­
TPI for the prediction of outcome of rtP A treatment in daily practice. 
Methods - From a prospectively generated database comprising 301 
consecutive stroke patients treated with intravenous rtP A, we calculated 
probabilities of good outcome (modified Rankin scale (mRS) 0-1 )  and 
very poor outcome (mRS 5-6) by using the s-TPI. We compared these 
probabilities with the observed outcome using receiver-operator 
characteristics (ROC) curves and calibration curves. We also performed 
subgroup analyses for different onset to treatment time windows. 
Results - According to the s-TPI, the mean predicted probability of a 
good and a very poor outcome in the validation cohort were 0.45 and 
0.17, respectively. The area under the ROC curves were 0.80 (4.5 hour 
time window), 0.82 (3 hour time window) and 0.77 (3-4.5 hours time 
window) for predicting good outcome, and 0.78 (4.5 hours), 0.80 (3 
hours) and 0.74 (3-4.5 hours) for predicting very poor outcome. 
Calibration curves revealed a slight overestimation of probabilities of a 
good outcome and underestimation of probabilities of a very poor 
outcome. 
Conclusions - The s-TPI appears to be reasonably valid for predicting 
outcome after rtP A treatment in daily practice. The slight overestimation 
of a good and underestimation of a very poor outcome may be explained 
by population differences between the derivation and validation cohort. 
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Introduction 
Treatment of acute ischaemic stroke with recombinant tissue 
plasminogen activator (rtP A) within 3 hours of symptom onset improves 
clinical outcome after 3 months.1 Although the first trials with rtP A were 
published approximately 10 years ago, t,3-5 it is still uncertain which 
patients are most likely to benefit from treatment. Adequate patient 
selection is very important, because the treatment carries a risk of serious 
haemorrhagic complications. The stroke-thrombolytic predictive 
instrument (s-TPI) was developed to aid clinicians in decision making 
and counseling of patients and familiy.2•6 The s-TPI is based on 
predictive variables for good (modified Rankin scale score (mRS) 0-1) or 
very poor outcome (mRS 5-6) generated from a pooled database from 5 
major randomised placebo controlled rtP A stroke trials. The calculated 
probability for good outcome is based on the following variables: age, 
diabetes, rtPA treatment, stroke severity as measured with the National 
Institute of Health Stroke Scale (NIHSS) score, gender, prior stroke, 
systolic blood pressure (SBP) and onset-to treatment time, together with 
four interaction terms between rtPA treatment and gender, SBP, prior 
stroke, onset to treatment time, and one interaction term between age 
and NIHSS score. Variables included in the model predicting very poor 
outcome were age, NIHSS score and serum glucose levels, whereas rtP A 
treatment was not included. 
The s-TPI is available on a website (the address is reported the 
Methods section) and by entering the patient characteristics the s-TPI 
calculates probabilities for either a good (with and without rtPA) or a 
very poor outcome. Although internal validation of the s-TPI has been 
performed by bootstrap sampling in a test dataset of the 5 trials, 2'6 it is 
uncertain whether this instrument is applicable to daily practice. 
In this study, we aimed to investigate the external validity of the s­





Single center validation cohort 
In 2002, an ongoing prospective registry of consecutive ischaemic stroke 
patients receiving rtPA treatment was started at the University Medical 
Center Groningen. For this study we analysed all patients included until 
October 2006. Inclusion and exclusion criteria for rtP A treatment were 
based on the National Institute of Neurological Disorders and Stroke 
rtPA Stroke Study Group (NINDS) trial protocol1 for patients treated 
within 3 hours of stroke onset. Based on the results of the pooled 
analysis of 5 randomised rtPA trials,7 rtPA treatment was also offered 
off-license to patients up to 4.5 hours after stroke onset.8 For treatment 
between 3 and 4.5 hours, we excluded patients with early ischaemic 
changes of more than one third of the middle cerebral artery territory on 
a brain CT scan. No upper age limit was defined. 
All patients were treated under monitoring on the stroke care unit, 
and received protocolled standard care, including early rehabilitation. 
Demographics and clinical information ( stroke characteristics, risk 
factors, treatment, complications and outcome) were prospectively 
recorded in a database. Symptomatic intracerebral haemorrhage was 
defined as a neurological deterioration within 48 hours after rtP A 
treatment with an intracranial hematoma on brain CT scan explaining 
the deterioration. All patients were scored on the modified Rankin Scale 
(mRS) at 3 months by a trained stroke nurse. 
Assessment of validity 
For each patient in our cohort, we calculated the probability of a good 
outcome (mRS 0-1) with and without rtP A using the multivariable model 
incorporated in the s-TPI. A detailed description of the probability 
equations is given in Table 1. The parameter estimates (�) from the 
logistic regression equation, as reported by Kent et al,2 were multiplied 
with the corresponding variable values (x). Although all our patients 
received rtPA, interaction terms of SBP, gender, prior stroke and time 
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until treatment with rtP A were included in the probability calculation. 
The same procedure was performed for the model predicting very poor 
outcome (mRS 5-6). The accuracy of calculated probabilities was 
checked by randomly entering data from patients on the website of the s­
TPI (accessed at http://ems-tipiis.com/ asat/index.jsp, May 2007). 
Sensitivity and specificity analyses of the s-TPI model were 
performed using receiver operator characteristic (ROC) curves.9 A ROC 
curve plots the sensitivity against 1 -specificity, and the area under the 
curve gives an impression of the discriminative capacity of the s-TPI. 
An area of 1 represents perfect discrimination, an area of 0.5 no 
discrimination. An area above 0.8 is considered to reflect good 
discrimination.10'11 
To investigate the reliability of the s-TPI, calibration curves were 
made. These curves plot the mean predicted probability against the 
observed rate of a good outcome stratified by quintiles, and give a visual 
impression about the accuracy of prediction in the whole range of 
probabilities. The most ideal calibration follows a line with an angle of 45 
degrees. This technique for assessing model performance has been 
described in other validation studies.1 0'12 The absolute error for 
calibration was calculated by subtracting the predicted probabilities from 
the observed outcomes. 
The s-TPI was separately tested for the three different onset to 
treatment time windows: 4.5 hours, 3 hours, and between 3-4.5 hours. 
All statistical analyses were done using SPSS statistical software 
package version 1 4.0 (SPSS Inc, Chigago, USA). ROC and calibration 
curves were made with Microsoft Excel 2003 for Windows. 




Table 1: Probability equations for good and very poor outcome 
Parameter good outcome 
xl = rtPA treatment (1= yes, 0 = no) 
x2 = Age (continuous), per year 
Parameter poor outcome 
xl = Age (continuous), per year 
x2 = NIHSS (continuous), per point 
x3 = Systolic blood pressure (continuous), per mm Hg x3 = Serum glucose (continuous), per mmol/1 
x4 = Diabetes (1 = yes, 0 = no) 
xS = Gender (male = 1, female =0) 
x6 = NIHSS (continuous), per point 
x7 = Prior stroke (1 = yes, 0 = no) 
x8 = Onset to treatment time (continous), per minute 
Probability of good outcome = 1 I (1 + e-Untercept + �1*x1 + �2*x2 + �3*x3 + �4*x4+ �S*xS + �6*x6 + �7*x7 + �8*x8 + �9*x1*x3 + 
�10*x1*x5 + �1 1*x1*x7 + �12*x1*x8 + �13* x2*x6J) . 
Probability of very poor outcome = 1 / (1 + e-[imercept + �1 *xl + �2*x2 + �3*x3]) 
For the parameter estimates of the s-TPI (� values) we refer to table 2 and 3 of the original article2 
� 
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Results 
Validation cohort 
Of the 301 patients included, 1 88 (63%) were treated within 3 hours of 
stroke onset. Characteristics of the validation cohort are presented in 
table 2. The validation cohort had a shorter onset to treatment time, 
older age, lower incidence of known arterial hypertension and diabetes 
mellitus, and a higher incidence of atrial fibrillation, compared to the 
baseline characteristics of the pooled trial data. 2 In the validation cohort, 
35% had a good outcome and 26% had a very poor outcome. 
s-TPI predicting good outcome 
The mean predicted probability of good outcome with rtPA was 0.45 
(median 0.45, range 0.02 - 0.93) versus 0.35 (median 0.31 , range 0.01 -
0.87) without rtPA in the 4.5 hour time window group (p < 0.001) .  
Forty-six patients (1 5 .3%) were predicted to have an equal or lower 
chance of a good outcome with rtP A than without rtP A. 
In the 3 hour time window group, the mean predicted probability 
was 0.46 (median 0.45, range 0.02 - 0.93) with rtPA, and 0.32 (median 
0.28, range 0.01 - 0.87) without rtPA (p < 0.001) .  The mean predicted 
probability with rtPA was 0.45 (median 0.47) and without rtPA 0.39 
(median 0.38) in the 3-4.5 hours group (p<0.001) .  
The ROC curve, presented in figure 1 ,  revealed an area under the 
curve of 0.80 (95% CI 0.75 - 0.85) for the 4.5 hour window group, 0 .82 
(0.76 - 0.88) for the 3 hour group, and 0.77 (0.68 - 0.86) for the 3-4.5 
hours group. 
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Table 2: Characteristics of the validation and the pooled trials I Q 
Validation cohort Pooled trial data5 I \a 
Time window 4.5 Time window 3 Time window 3-4.5 Time window 6 
hours (n=301) hours (n=1 88) hours (n= 1 1 3) hours (n=2131) 
Mean age, yrs (SD) 67.9 (14.4) 68.1 (14.2) 67.7 (14.8) 65.9 (1 1 .4) 
Gender, male 1 58 (53) 92 (49) 66 (58) 1 166 (55) 
Median NIHSS (IQR) 13 (8-17) 14 (9-17) 12 (7-16) 12 (8-17) 
>--I- Median OTT (IQR) 175 (140-210) 150 (120-165) 225 (207-240) 235 (1 55-290) 
Mean SBP, mm Hg (SD) 153.7 (27.7) 1 52.1 (25.6) 1 56.4 (30.8) 1 52.6 (20.3) 
Mean DBP, mm Hg (SD) 83.1 (1 5.9) 81 .8 (13.5) 85.4 (19.1) 
Mean glucose, mmol/L (SD) 6.4 (1 .9) 6.3 (1 .7) 6.5 (2.2) 6.8 (median) 
Diabetes 36 (12) 20 (1 1) 16 (14) 443 (21) 
Prior stroke/TIA 52 (17) 29 (1 5) 23 (20) 353 (17) 
Hypertension 134 (45) 82 (44) 52 (46) 1245 (59) 
Atrial fibrillation 76 (25) 45 (24) 31  (27) 394 (19) 
� 
� 
Table 2: Continued 
Validation cohort Pooled trial data5 
Time window 4.5 Time window 3 Time window 3-4.5 Time window 6 
hours (n=301) hours (n=188) hours (n=l 13) hours (n=2131) 
sICH 18 (6) 12 (6.4) 6 (5.3) 
mRS 0-1 after 3 months 104 (35)* 64 (34) 40 (36)* 773 (36) 
mRS 5-6 after 3 months 77 (26)* 50 (27) 27 (24)* 464 (22) 
Values are numbers (%) unless otherwise indicated. *1 missing mRS score. 
SD = standard deviation, IQR = interquartile range, NIHSS = National Institute of Health Stroke Scale, OTT = 
onset to treatment time, SBP /DBP = systolic/ diastolic blood pressure, TIA = transient ischaemic attack, SICH = 













s-TP I pred icti ng good outcome 
-- 0-4.5 h 
- - - - - - - 0-3 h 
- - - - 3-4.5 h 
0 ---------�------,-------,------1 
0 0,2 0,4 0,6 0,8 
1 -specificity 
Figure 1: "Receiver operator characteristic curves of s-TPI models predicting good 
outcome for the 3 different time windows 
s-TPI predicting poor outcome 
The mean predicted probability of poor outcome was 0. 17  (median 0. 1 3, 
range 0.01 - 0.73) in the 4.5 hour group. For the 3 hour group the mean 
and median predicted probabilities were 0. 1 8  and 0 . 1 5  (range 0.01 -
0.72), and for the 3-4.5 hours group 0. 1 6  and 0. 1 2  (range 0.01 - 0.73) .  
The area under the ROC curve was 0.78 (95% CI  0.72 - 0.84) for 
the 4.5 hour group, 0.80 (95% CI 0.73 - 0.87) for the 3 hour group, and 
0.74 (95% CI 0.63 - 0.85) for the 3-4.5 hours group (figure 2) . 
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-- 0-4.S h 
- - - - - - · 0-3 h 
- - - - 3-4.5 h 
0 -----------�----------1 
0 0,2 0,4 0,6 0,8 
1 -specificity 
Figure 2: Receiver operator characteristic curoes of s-TPI models predicting very poor 
outcome far the 3 different time windows. 
Model calibration 
The calibration curves are presented in figure 2. The curves for good 
outcome show that the mean predicted probability of good outcome was 
somewhat higher than the actual rate of good outcome in all quintiles. 
On the other hand, the mean predicted probability of a very poor 
outcome was lower than the actual rate of very poor outcome. This 
trend was observed for each of the 3 different time windows. In the 
upper quintiles of probabilities, the prediction of a very poor outcome 
was less accurate than in the lower quintiles. The mean absolute error 
was 0.37 for the model predicting good outcome and 0.29 for the model 
predicting poor outcome in the entire cohort. 
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--+--- Obsen.ed 0-4.5 h 
- - -•· - - Obsen.ed 0-3 h 
- * - Obsen.ed 3-4.5  h 
-- Ideal 
0 
0 0,2 0,4 0,6 0,8 
Mean predicted probability good outcome 











ro --+--- Obsen.ed 0-4.5  h 
;:J 0 ,2 u - - · •· - - Obsen.ed 0-3 h 
<( - * - Obsen.ed 3-4.5  h 
-- Ideal 
0 
0 0 ,2 0,4 0,6 0,8 
Mean predicted probability very poor outcome 
Figure 2: Calibration curves for the s-TPI predicting good and very poor outcome. 
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Discussion 
This study demonstrates that the s-TPI has an acceptable external 
validity for the prediction of outcome after intravenous rtP A treatment 
for ischaemic stroke in daily clinical practice. There were no important 
differences in the prediction of good or very poor outcomes between the 
3-hours time window and the 3-4.5 hours time window. 
Regarding the discriminative capacity of the s-TPI, the area under 
the ROC curves were similar to those found in the internal validation 
procedure.2 The mean absolute errors were in both models less than 0.4. 
This threshold has previously been used to define acceptable 
calibration. 10 The s-TPI appeared to overestimate good and 
underestimate very poor outcome in rtP A treated patients, which was 
demonstrated by the calibration curves. Over the whole range, patients 
were more likely to have a good outcome or less likely to have a very 
poor outcome than the observed outcomes in our study cohort. 
Especially in the higher range of probabilities, prediction of very poor 
outcome was underestimated. This may be explained by differences in 
clinical profile between routinely treated patients and those included in 
the randomised rtP A trials. A common point of criticism about the 
randomised rtP A trials is that patients were highly selected, which may 
affect the external validity. 13'1 4  An example of an important difference 
between the trial population and our cohort is the fact that 25% of our 
patients were aged 80 years or older, while in the pooled trial data, only 
42 of the 2130 (2%) patients were older than 80 years, with only the 
NINDS study not excluding patients older than 80 years. Older stroke 
patients treated with intravenous rtP A have a worse prognosis compared 
to their younger counterparts.15'16 There were also differences in the 
prevalence of comorbidity between patients from the pooled data2 and 
those in our cohort.. 
A strong point of this study is that the validation cohort reflects a 
population of thrombolysed patients in daily clinical practice. Our study 
shows that the s-TPI is not only capable to predict outcome in rtP A 
treated patients within the 3-hour window, but also within the 3-4.5 
hours window. Since we treated patients up to 4.5 hours, our cohort was 
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particularly suited to validate the prediction of outcome in this extended 
time window. 
Our study has limitations. The s-TPI is developed to select patients 
who are most likely to benefit from rtP A and since we could not include 
a control group in our study, the relative benefit from rtP A on functional 
outcome compared to placebo was not investigated. The sample size of 
our study is relatively small compared to sample size of the derivation 
cohort. Nevertheless, the patient-characteristics of our cohort were not 
very different compared to those of other rtP A treated cohorts outside a 
trial setting.11-20 
In summary, the s-TPI appears to be a useful instrument for 
predicting good or very poor outcome in stroke patients who are treated 
with intravenous rtP A in daily clinical practice, although it may give a 
slight overestimation of a good outcome and underestimation of a very 
poor outcome. 
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In the last years, the management of patients with acute ischaemic stroke 
has changed substantially. The development of stroke units 1'2 and the 
introduction of thrombolytic therapy3 has led to a tremendous 
improvement of acute stroke care. Currently there is much interest in the 
development of additional reperfusion and neuroprotective strategies 
aimed at rescuing cells in the ischaemic penumbra. Identifying factors 
that enhance or prevent the conversion of penumbra to infarct core, may 
provide new insights for acute stroke therapies. Despite promising 
results of neuroprotective compounds in animal models, human studies 
were all disappointing. One of the reasons for this failure may be 
explained by the use of insensitive, inappropriate or inconsistent 
outcome measures. 4'5 Optimising the definition of outcome after stroke 
is therefore important to improve the quality of future stroke trials. 
Another possible explanation may be the fact that only few stroke trials 
stratified their outcome analyses for different ischaemic stroke subtypes, 
while it is well known that the pathophysiology and prognosis of these 
subtypes is variable.6-8 For example, neuroprotective treatments may 
respond differently in the gray or white matter. It has therefore been 
suggested that the different gray /white matter ratio between animals and 
humans may be responsible for the fact that neuroprotective drugs did 
work in animals models but not in stroke patients.9 
Treatment of acute ischaemic stroke with recombinant tissue 
plasminogen activator (rtP A) is one of the therapies that aims to protect 
the ischaemic penumbra against irreversible damage by restoring the 
cerebral blood circulation. Although a single randomised controlled trial 
and a meta-analysis demonstrated that rtPA improves functional 
outcome,3'1 0  thrombolytic therapy is still underused, even in eligible 
stroke patients. 1 1 Increasing the knowledge about prognostic factors in 
rtP A treated patients, may contribute to an evidence based approach of 
selection of patients eligible for this treatment and assist stroke 
physicians in clinical decision making. 
The aim of this thesis was threefold. Firstly, the relation between 
two frequently used outcome measures, the Barthel Index (BI) and 
modified Rankin Scale (mRS), was explored. We tried to find an optimal 
way to define outcome with these scales and investigated how these 
scales were used in two large stroke trials. Secondly, the role of 
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hyperglycaemia in acute ischaemic stroke was examined, taking the 
different stroke subtypes (lacunar versus non-lacunar) into account. 
Thirdly, we investigated various prognostic variables for and safety 
aspects of rtP A treatment and performed several subgroup-analyses in 
patients who received rtP A. 
Outcome assessment in acute ischaemic stroke 
The relation between the BI and the mRS, which are the two most 
frequently used outcome measures in acute stroke, was explored in 
Chapter 2 and 3. Both scales have been extensively investigated with 
regard to their clinimetrical properties such as validity, reliability and 
responsiveness,12-19 but there is no consensus on which scores should be 
used to define outcome in acute stroke. 20 In Chapter 2, we aimed to 
determine corresponding cut-off scores on the BI and mRS. Three 
different degrees of disability were assessed. The corresponding BI cut­
off scores were � 9 5 for mRS :::; 1, � 90 for mRS :::; 2 and � 7 5 for mRS 
:::; 3, reaching the highest combination of sensitivity and specificity. The 
use of these combined dichotomised cut-off scores in future stroke trials 
may contribute to a consistent and uniform way to define outcome. 
In Chapter 3, the relation between the BI and mRS was explored in 
more detail. There was a considerable overlap of BI scores in mRS 
grades 0, 1 and 2. Among patient with a mRS score of 1 or 2, which 
represents independency for ADL, a substantial number of patients 
needed help on one or more items of the BI, which suggest they were 
not independent. On the other hand, approximately a quarter of the 
patients with mRS 3 needed assistance when walking, which should 
result in at least a mRS score of 4. This suggests that the mRS may be 
scored in a subjective manner in acute stroke trials. Wilson et al showed 
that using a structured interview increased the reliability of the mRS.21 •22 
The BI, however, may not be suited to reclassify, or structure the mRS, 
since these scales lack items such as aphasia and cognitive impairments. 




Hyperglycaemia in acute ischaemic stroke 
One of the factors which is considered to negatively influence the 
survival of the penumbra is an elevated blood glucose level at stroke 
onset. We found a different relationship between hyperglycaemia and 
stroke outcome in lacunar and non-lacunar infarctions, as described in 
Chapter 4. While hyperglycaemia was associated with worse outcome in 
non-lacunar stroke, it was actually associated with favourable outcome in 
lacunar infarctions. A previous study had also shown this discrepancy,23 
but this observation had never been confirmed until now. 
The association between hyperglycaemia and worse outcome in non­
lacunar stroke has been emphasized in many previous studies, but is 
unclear whether this is a causal relationship. Some have argued that 
hyperglycaemia is a reflection of an acute stress response and that the 
worse outcome was more a reflection of the stroke severity than an 
independent effect of hyperglycaemia,24'25 however, in another study 
there was no relation between glucose levels and stress related hormones 
during acute stroke. 26 On the other hand, hyperglycaemia increases 
lactate concentration, which in turn was related to a reduced survival of 
the penumbra, independent of the initial stroke severity.27 This finding 
supports the hypothesis that hyperglycaemia has direct neurotoxic effects 
in non-lacunar infarctions. 
The exact cortical location of ischaemia may also play a role in the 
development of hyperglycaemia. Involvement of the insular cortex, in 
which autonomic efferent projections are located, appeared to be 
associated with hyperglycaemia in a single study using diffusion weighted 
MR imaging,28 but this finding could not be reproduced by two other 
studies using (perfusion) CT imaging. 29,30 
Lacunar infarctions presenting with hemiparesis are often located in 
the deep white matter. We hypothesised that in acute lacunar stroke, 
lactate produced by astrocytes surrounding the axons may serve as an 
energy source31 and rescue the axons and oligodendrocytes.32'33 
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Interestingly, the recently published Glucose Insulin in Stroke Trial 
did not demonstrate a beneficial effect of lowering elevated blood 
glucose in acute stroke.34 Moreover, the patients with the greatest 
reduction of blood glucose, had higher mortality rates. No differences 
were found in subgroup analyses including stratification for stroke­
subtype. 34 
Thrombolysis for acute ischaemic stroke 
Chapters 5-9 describe the results of rtPA treatment at the University 
Medical Center Groningen. In Chapter 5, we evaluated rtP A treatment 
between 3 and 4.5 hours after stroke onset and compared these results 
with treatment started within 3 hours. The risk of SICH was not 
increased in this time window compared to rtP A treatment started within 
3 hours of stroke onset even when we adjusted for differences in 
baseline characteristics. Mortality rates and the number of patients with 
an independent functional outcome at 3 months were not different in 
both time windows. This suggests that the safety profile of rtP A 
treatment in the 3 to 4.5 hour time window is comparable to treatment 
within 3 hours. Although a post-hoc analysis of the large rtPA trials 
showed a beneficial effect beyond 3 hours,35 the question whether rtP A 
is still effective compared to placebo in the 3-4.5 hour time window 
remains to be answered by the ECASS-3, a randomised placebo 
controlled trial of which the results are expected in June 2008. 
In Chapter 6, we studied the outcomes of rtP A treatment in 
patients aged 80 years or older. There was no difference in incidence of 
SICH following rtPA treatment between patients younger or older than 
80 years. Early mortality (within 7 days) was also comparable, but at 3 
months older patients had a higher death or dependency rate than the 
younger patients. The worse 3-month outcome, however, may be more 
related to an increased vulnerability and a higher prevalence of 
comorbidity in the elderly than to an independent effect of rtP A 
treatment. These results were comparable with those of other cohort 
studies.36 The Third International Stroke Trial (IST-3), is currently 
ongoing and randomises patients older than 80 years to rtP A or placebo. 
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In Chapter 7, the safety of antiplatelet (AP) treatment before rtP A 
was studied. We observed a higher incidence of SICH in patients on 
prior AP therapy than the patients without prior AP therapy. Patients 
with AP are likely to have had more previous vascular events and are 
more often tainted with vascular risk factors than patients without prior 
AP. This imbalance may have confounded the results, but after 
adjustments for several potential confounders, prior AP therapy was 
independently associated with SICH. The functional outcome at three 
months was comparable in patients with and without SICH. When 
adjusting for confounders, prior AP was independently associated with 
favourable outcome. A possible favourable effect of AP may be 
explained by the prevention of early re-occlusions after rtP A treatment. 
In epidemiological cohortstudies, a randomised controlled trial and a 
systematic review, an increased risk of ICH in patients with low 
cholesterol levels was observed.37-41 In Chapter 8 we investigated the 
influence of cholesterol levels, triglyceride levels, statin use on the risk of 
SICH and on clinical outcome. Patients with SICH had no lower 
cholesterol levels and did not use statins more often than patients 
without SICH. Triglyceride levels were significantly higher among 
patients with SICH. In a multivariable analysis, higher triglyceride levels 
were independently associated with a higher risk of SICH. Whether this 
is a causal and consistent relation remains to be elucidated in further 
studies. No relation between lipid profile and clinical outcome was 
observed. 
In Chapter 9, we evaluated the use of the stroke thrombolytic 
predictive instrument (s-TPI) in daily clinical practice. The aim of the s­
TPI is to provide individual patient predictions for a good or very poor 
outcome after receiving ( or not receiving) rtP A treatment. We checked 
the accuracy of the prediction of good and very poor outcome after rtP A 
treatment. The discrimination into good or no good and very poor or 
not very poor outcome was reasonable. The chance of a good outcome 
tended to be overestimated and the chance of a very poor outcome 
tended to be underestimated. The fact that the s-TPI has been derived 
from trial data, in which patients were highly selected patients, may 
explain this over-optimistic trend. The s-TPI may be applied to estimate 
the prognosis after t-PA treatment but it should be further evaluated 
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whether the s-TPI is accurate in selecting patients for or exclude patients 
from rtP A treatment. 
Practical implications of the thesis and future directions 
This thesis provides further insights on a better design of future stroke 
trials and on how acute stroke care may be further optimised. 
Firstly, the optimal cut-off scores on the BI and mRS may be used 
by stroke physicians in future clinical trials and for scoring the mRS 
more accurately, a structured interview may be helpful. 
Secondly, we observed that the relation between hyperglycaemia and 
functional outcome was different between lacunar and non-lacunar 
infarctions. This implies that future trials aimed at lowering blood 
glucose should distinguish lacunar from non-lacunar infarctions. 
Thirdly, rtP A treatment may be extended to certain subgroups of 
patients, ( e.g. patients presenting after 3 hours of stroke onset and 
patients aged 80 years and older) as this appeared to be relatively safe 
and there are indications that these subgroups are likely to benefit from 
rtP A treatment. Although prior AP was associated with an increased risk 
of SICH, rtPA treatment should not be withheld in these patients, as 
there are also indications that prior AP may be associated with better 
outcome. A definite answer whether rtP A is effective in these subgroups 
cannot yet be given. At the moment, there is no reason to exclude 
patients with low cholesterol levels or statin therapy from rtP A 
treatment. Adequate patient selection for rtP A treatment is of extreme 
importance. At the moment the s-TPI could be used in daily practice to 
get an impression about the prognosis after rtP A treatment. Selecting 
patients with imaging techniques, such as perfusion CT or 
perfusion/ diffusion MRI, by quantifying the ischaemic penumbra, has 
shown promising results42'43 and the efficacy of this approach is currently 
being investigated in prospective trials. The use of both clinical and 
imaging criteria has the potential to increase the numbers of patients 
which will be eligible for rtP A treatment especially by extending the time 
window for rtP A treatment. Besides intravenous thrombolysis, local 
recanalisation therapies have shown promising results. To further 
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improve acute stroke treatment, more aggressive recanalisation therapies 
may be considered after failure of systemic thrombolysis, for example by 
IA thrombolysis or by mechanical embolectomy. 44-47 
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De behandeling van het acute herseninfarct is de laatste jaren aanzienlijk 
verbeterd door de ontwikkeling van 'stroke units' en cerebrale 
trombolyse. Momenteel wordt er volop onderzoek gedaan naar 
aanvullende behandelingen gericht op het beschermen van de 
ischemische penumbra (gebied in de hersenen waarin een verminderde 
bloedtoevoer ervoor zorgt dat de zenuwcellen niet meer goed 
functioneren, maar waarbij nag niet per se irreversibele schade is 
ontstaan). Het achterhalen van factoren die de penumbra beschermen 
(neuroprotectie) of juist schaden (neurotoxiciteit) zou kunnen bijdragen 
aan rueuwe behandelingen. Bij dierexperimentele studies leken 
verscheidene neuroprotectieve stoffen veelbelovend, echter bij humane 
studies verbeterde de prognose na het herseninfarct niet met 
neuroprotectiva. Een mogelijke verklaring voor deze teleurstellende 
resultaten zou kunnen liggen in het feit dat deze studies ongevoelige, 
inadequate of irrelevante schalen gebruikten voor het bepalen van de 
uitkomst na een herseninfarct. Het is clan ook van belang voor 
toekomstige studies om de uitkomst zo goed mogelijk te definieren, om 
de kwaliteit van deze studies te verhogen. Een andere mogelijke 
verklaring voor de negatieve resultaten is het gegeven dat weinig studies 
hun resultaten hebben gestratificeerd voor de verschillende subtypes van 
het herseninfarct. De pathofysiologie en prognose van de herseninfarct­
subtypes zijn namelijk verschillend. N europrotectiva zouden een ander 
effect kunnen hebben op de witte stof clan op de grijze stof in de 
hersenen. De verschillende verhouding tussen grijze en witte stof bij 
dieren en mensen zou daarom een van de redenen kunnen zijn waarom 
in het verleden neuroprotectiva wel bij dieren maar niet mensen effectief 
waren. 
De ratio achter cerebrale trombolyse met recombinant weefsel 
plasminogeen activator (rtP A) voor de behandeling van het herseninfarct 
is het voorkomen van irreversibele schade in de penumbra door zo 
spoedig mogelijk de bloedtoevoer naar dit gebied weer te herstellen. 
Hoewel de behandeling met rtP A effectief is gebleken in gerandomiseerd 
onderzoek en volgens een meta-analyse, wordt deze therapie bij maar 
weinig patienten met een herseninfarct toegepast, zelfs wanneer de 
omstandigheden wel optimaal zijn. Het onderzoeken van prognostische 
factoren kan bijdragen aan een betere selectie van patienten met een 
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herseninfarct geschikt voor behandeling met rtP A en kan clinici 
ondersteunen in de besluitvorming random deze behandeling. 
De doelstelling van dit praefschrift was drieledig. In eerste instantie 
werd gekeken naar de relatie tussen twee frequent gebruikte schalen om 
de uitkomst na een herseninfarct te meten, de Barthel Index (BI) en de 
"modified Rankin Scale" (mRS). We hebben onderzocht hoe we zo 
optimaal mogelijk de uitkomst na een herseninfarct kunnen meten met 
deze schalen en hoe deze schalen zijn toegepast in twee grate studies met 
neuropratectiva. Het tweede onderwerp van dit praefschrift gaat over de 
pragnostische waarde van een verhoogd serum glucose (hyperglykemie) 
ten tijde van een acuut herseninfarct, waarbij rekening werd gehouden 
met de verschillende herseninfarct-subtypes. In het derde deel van dit 
praefschrift werd gekeken naar pragnostische factoren voor de uitkomst 
na en veiligheidsaspecten random cerebrale trombolyse met rtP A en zijn 
verschillende subgroepanalyses verricht. 
Meten van uitkomst na een herseninfarct 
De relatie tussen de BI en mRS, de meest frequent toegepaste 
uitkomstschalen bij herseninfarcten, werd bestudeerd in hoofdstukken 
2 en 3. Hoewel de klinimetrische eigenschappen, zoals validiteit, 
betrauwbaarheid en responsiviteit, van beide schalen al eerder uitgebreid 
zijn bestudeerd, bestaat er tot op heden geen consensus welke 
afkappunten op de schalen het best gebruikt kunnen warden om de 
uitkomst te definieren. In hoofdstuk 2 hebben we gekeken welke scores 
op de BI en mRS met elkaar overeenkomen. De afkappunten met een 
maximale sensitiviteit en specificiteit waren: BI � 9 5 voor mRS ::; 1, BI 
� 90 voor mRS ::; 2 en BI � 7 5 voor mRS ::; 3. Het gebruiken van deze 
gecombineerde afkappunten draagt bij aan een consistente en uniforme 
manier om eindpunten in studies naar herseninfarcten te definieren. 
De gedetailleerde relatie tussen de BI en mRS werd onderzocht in 
hoofdstuk 3. De verdeling van BI scores in mRS scores 0, 1 en 2 was 
nauwelijks verschillend. Een aanzienlijk deel van de patienten met een 
mRS score van 1 of 2, hetgeen betekent dat ze ADL zelfstandig zouden 
moeten zijn, had hulp nodig op tenminste 1 item van de BI. Van de 
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patienten met een mRS 3 had bijna een kwart hulp nodig met lopen, 
hetgeen de definitie van een mRS 4 is. Deze bevindingen suggereren dat 
patienten op een subjectieve manier gescoord warden op de mRS. Het is 
aangetoond dat een gestructureerd interview de betrouwbaarheid van de 
mRS doet toenemen. Desondanks lijkt de BI niet geschikt als instrument 
om de mRS nauwkeuriger te graderen, ondermeer omdat de BI enkele 
items niet meeneemt. Deze items, zoals bijvoorbeeld afasie of cognitieve 
stoornissen, zijn wel degelijk relevant voor pat1enten met een 
herseninfarct en ook de mate van beperkingen na een herseninfarct 
bei'nvloeden. 
Hyperglykemie tijdens de acute fase van het herseninfarct 
Een van de factoren waarvan men verondersteld dat die een negatieve 
invloed uitoefent op de penumbra, is een verhoogd serum glucose. In 
hoofdstuk 4 werd een verschillend verband tussen hyperglykemie en de 
prognose bij lacunaire en niet-lacunaire (corticale) infarcten gevonden. 
Hyperglykemie was geassocieerd met een slechte prognose bij niet­
lacunaire infarcten maar leek mogelijk bij lacunaire infarcten geassocieerd 
met een betere prognose. Deze discrepantie is ooit eerder al eens 
beschreven, maar nooit bevestigd. 
Het verband tussen hyperglykemie en een slechte prognose bij 
corticale infarcten was al langer bekend, hoewel het niet zeker is of dit 
daadwerkelijk een causaal verband is. Sommigen hebben geopperd dat 
hyperglykemie een weergave is van een acute stressreactie en dat de 
slechte prognose dus meer verklaard wordt door de ernst van het infarct 
clan door een onafhankelijk effect van hyperglykemie zelf. Tijdens 
hyperglykemie en acute ischemie is er een verhoogde lactaatproductie, 
hetgeen leidt tot het sneller afsterven van cellen in de penumbra. Dit 
ondersteunt de hypothese dat hyperglykemie een direct neurotoxisch 
effect heeft bij niet-lacunaire infarcten. 
De corticale lokalisatie van het infarct speelt mogelijk ook een rol in 
het ontstaan van een verhoogd glucose. In een studie is gebleken dat een 
infarct in de insulaire cortex, van waaruit autonome efferente zenuwen 
projecteren, onafhankelijk geassocieerd was met het optreden van 
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hyperglykemie. Latere studies konden dit fenomeen echter niet 
bevestigen. 
Lacunaire infarcten die zich manifesteren met een hemiparese, zijn 
vaak gelokaliseerd in de witte stof. We postuleerden een hypothese dat 
bij lacunaire infarcten, het lactaat dat geproduceerd wordt door 
astrocyten rondom axonen als energiebron gebruikt kan worden en op 
die manier de astrocyten en oligodendrocyten kan beschermen. 
De recent gepubliceerde "Glucose Insulin in Stroke Trial" liet geen 
gunstig effect zien van het verlagen van een verhoogd serum glucose op 
de prognose na een herseninfarct. De patienten met de grootste reductie 
in serum glucosewaarden hadden zelfs een hogere mortaliteit. In een 
subgroepanalyse werden geen verschillen gevonden, ook niet tussen de 
verschillende subtype herseninfarcten. 
Cerebrale trombolyse voor het acute herseninfarct 
Hoofdstukken 5-9 beschrijven de resultaten van de trombolyse 
behandeling met rtPA bij het acute herseninfarct in het Universitair 
Medisch Centrum Groningen. In hoofdstuk 5 hebben we gekeken naar 
het effect van rtP A wanneer de behandeling pas 3 tot 4.5 uur na ontstaan 
van de klachten gestart kon worden. Hierbij werd gebruik gemaakt van 
een apart protocol dat deels gebaseerd is op de ECASS-2 studie. Het 
risico op een symptomatische intracerebrale bloeding (SICH) was niet 
verhoogd in vergelijking met behandeling binnen 3 uur na het ontstaan 
van de klachten. Het aantal patienten met een goede uitkomst (ADL 
onafhankelijk) was vergelijkbaar en ook de mortaliteit was niet 
verschillend in beide groepen. Deze resultaten suggereren dat de 
veiligheid van rtP A behandeling 3 en 4.5 uur na het ontstaan van de 
klachten vergelijkbaar is met behandeling binnen 3 uur. Hoewel een 
post-hoc analyse van de drie grote rtPA studies suggereerde dat rtPA 
ook na 3 uur nog effectief is, zal het definitieve bewijs voor behandeling 
tussen 3 en 4.5 uur geleverd moeten worden door de ECASS-3, een 
gerandomiseerde placebo gecontroleerde trial. De resultaten hiervan 
worden verwacht in juni 2008. 
145 
Chapter 1 1  
In hoofdstuk 6 werd gekeken naar de prognose na rtP A 
behandeling bij patienten van 80 jaar of ouder. Er was geen verschil in de 
frequentie van SICH in vergelijking met patienten jonger clan 80 jaar. 
Ook de vroege mortaliteit was vergelijkbaar, maar de mortaliteit en het 
percentage patienten met een slechte uitkomst na drie maanden was 
aanzienlijk hoger bij de oudere patientengroep. Dit lijkt logischerwijs 
meer gerelateerd aan verhoogde kwetsbaarheid en kans op complicaties 
bij oudere patienten clan aan een direct effect van rtP A. Momenteel 
onderzoekt "The Third International Stroke Trial" de effectiviteit en 
veiligheid van rtP A bij onder andere patienten ouder clan 80 jaar. 
Hoofdstuk 7 gaat over de veiligheid van rtP A bij patienten die 
trombocytenaggregatieremmers (AP, bloedverdunners zoals bijvoorbeeld 
aspirine) gebruikten voorafgaand aan trombolyse. Bij deze patienten was 
de kans op SICH verhoogd ten opzichte van patienten zonder AP. 
Logischerwijs waren patienten met AP vaker ouder en belast met 
vasculaire risicofactoren, hetgeen mogelijke confounders kunnen zijn 
voor de relatie tussen AP en SICH. Na correctie voor deze confounders 
was voorafgaande AP behandeling onafhankelijk geassocieerd met SICH. 
De functionele uitkomst was vergelijkbaar tussen patienten met en 
zonder AP en na correctie voor confounders leek AP zelfs geassocieerd 
met een betere uitkomst. 
In eerdere studies werd bij patienten met lage cholesterol 
concentraties een verhoogd risico op primaire intracerebrale bloedingen 
geobserveerd. In hoofdstuk 8 werd de relatie tussen het gebruik van een 
statine, concentratie van cholesterol of triglyceriden en het risico op 
SICH na trombolyse onderzocht. De cholesterolconcentratie had geen 
relatie met SICH, maar een verhoogde triglycerideconcentratie wel, ook 
na correctie voor confounders. Behandeling met statines was niet 
geassocieerd met SICH. Geen van deze factoren was van invloed op de 
functionele uitkomst. 
De validiteit van de 'stroke-thrombolytic predicitive instrument' (s­
TPI), een instrument om in de dagelijkse praktijk de prognose na 
trombolyse te voorspellen, werd bestudeerd in hoofdstuk 9. De s-TPI 
voorspelt voor een individuele patient de kans op een goede of slechte 
uitkomst na rtPA (of wanneer geen rtPA gegeven wordt). We hebben 
gekeken naar de nauwkeurigheid van deze voorspellingen. De kans op 
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een goede of juist een slechte uitkomst kon door de s-TPI behoorlijk 
nauwkeurig warden voorspeld. De kans op een goede uitkomst werd wel 
overschat en de kans op een slechte uitkomst onderschat. Dit enigszins 
te optimistische beeld zou mogelijk verklaard kunnen warden door het 
feit dat de s-TPI ontwikkeld is aan de hand van gegevens, die afkomstig 
waren van een hoog geselecteerde patientenpopulatie die is geincludeerd 
in rtP A trials. 
Praktische consequenties en toekomst perspectieven 
Dit proefschrift biedt nieuwe inzichten hoe de kwaliteit van toekomstige 
studies random herseninfarcten en de behandeling van patienten met 
een herseninfarct verbeterd kunnen warden. Allereerst zouden de meest 
optimale afkappunten op de BI en mRS gebruikt kunnen warden voor 
nieuwe studies. Voor het afnemen van de mRS kan een gestructureerde 
scoringsmethode van belang zijn. 
Ten tweede hebben we aangetoond dat de relatie tussen 
hyperglykemie en de prognose verschillend is bij lacunaire en niet­
lacunaire infarcten. Dit houdt in dat toekomstige studies, die het nut van 
het verlagen van de glucoseconcentratie bij herseninfarcten onderzoeken, 
onderscheid moeten maken tussen niet-lacunaire en lacunaire infarcten, 
of mogelijk zelfs lacunaire infarcten kunnen excluderen. 
Ten derde zou men kunnen overwegen, op basis van de 
verschillende subgroepanalyses, om de behandeling met rtP A uit te 
breiden naar bepaalde patientengroepen. Het gaat clan om bijvoorbeeld 
patienten ouder clan 80 jaar, of patienten die tussen 3 en 4.5 uur na het 
ontstaan van de klachten behandeld kunnen warden, gezien dit relatief 
veilig lijkt te zijn. Er zijn ook indirecte aanwijzingen dat deze subgroepen 
baat hebben bij rtPA behandeling. Ondanks het feit dat AP voorafgaand 
aan trombolyse met rtP A geassocieerd werd met een verhoogde kans op 
SICH, lijkt dit geen contra-indicatie te zijn voor trombolyse. Er zijn 
namelijk ook aanwijzingen dat voorafgaand AP juist geassocieerd is met 
een betere uitkomst. Echter de vraag of rtP A effectief is in deze 
subgroepen, kan nog niet definitief beantwoord warden. Op dit moment 
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is er geen reden om patienten met statines of lage cholesterolwaarden te 
excluderen van rtP A behandeling. 
Het is dus bijzonder belangrijk om de juiste patienten voor rtP A 
behandeling te selecteren. De s-TPI zou een bruikbaar instrument 
kunnen zijn, ook in de dagelijkse praktijk, om een indruk te krijgen van 
de prognose na trombolyse. Daarnaast lijkt het selecteren van patienten 
aan de hand van beeldvormende technieken, zoals perfusie CT of 
perfusie/ diffusie gewogen MRI sequenties, veelbelovend. De effectiviteit 
van deze methode wordt momenteel onderzocht in meerdere 
prospectieve studies. Met gebruikmaking van zowel klinische als 
beeldvormende criteria zou het mogelijk kunnen zijn om het aantal 
patienten dat in aanmerking komt voor rtP A te vergroten. Dit kan in het 
bijzonder door het verlengen van het tijdsvenster van behandeling. Naast 
intraveneuze trombolyse, lijken ook lokale rekanalisatietherapieen 
veelbelovend. Zo zou bijvoorbeeld bij het uitblijven van een respons op 
intraveneuze trombolyse overwogen kunnen warden om tot lokale intra­





Appendix I: The modified Rankin Scale 
Grade Description 
0 No symptoms at all 
1 No significant disability despite symptoms; able to carry out 
all usual duties and activities 
2 Slight disability; unable to carry out all previous activities, but 
able to look after own affairs without assistance 
3 Moderate disability; requiring some help, but able to walk 
without assistance 
4 Moderately severe disability; unable to walk without assistance 
and unable to attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent and requiring 
constant nursing care and attention 
6 Dead 
The original Rankin scale did not contain grade 0, defined grade 1 as 'No significant 
disability: able to carry out all usual duties', and defined Grade 2 as 'Slight disability: 
unable to carry out some of previous activities.' 
1 50 
Appendix II: Barthel Index 
FEEDING 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent 
BATHING 
0 = dependent 
5 = independent ( or in shower) 
GROOMING 
0 = needs to help with personal care 
5 = independent face/hair/ teeth/ shaving (implements provided) 
DRESSING 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.) 
BOWELS 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent 
BLADDER 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent 
TOILET USE 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping) 
TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent 
MOBILITY (ON LEVEL SURFACES) 
0 = immobile or < 50 yards 
5 = wheelchair independent, including corners, > 50 yards 
10 = walks with help of one person (verbal or physical) > 50 yards 
15 = independent (but may use any aid; for example, stick) > 50 yards 
STAIRS 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 




Appendix Ill: NIH Stroke Scale (NIHSS) 
1.a. Level of Consciousness 
1.b. Ask patient the month and 
their age: 
0 Alert 
1 Not alert, but arousable with minimal stimulation. 
2 Not alert, requires repeated stimulation to attend. 
3 Coma 
0 Answers both correctly 
1 Answers one correctly 
2 Both incorrect 
1.c. Ask patient to open and close O Obeys both correctly 
eyes 1 Obeys one correctly 
2 Both incorrect 
2. Best gaze 
(only horizontal eye movement) : 
3. Visual Field testing: 
4. Facial Paresis (Ask patient to 
show teeth or raise eyebrows and 
close eyes tightly) : 
5. Motor Function - Arm 
(right and left) : 
0 Normal 
1 Partial gaze palsy 
2 Forced deviation 
0 No visual field loss 
1 Partial hemianopia 
2 Complete hemianopia 
3 Bilateral hemianopia (blind including cortical 
blindness) 
0 Normal symmetrical movement 
1 Minor paralysis 
(flattened nasolabial fold, asymmetry on smiling) 
2 Partial paralysis (total or near total paralysis of 
lower face) 
3 Complete paralysis of one or both sides 
(absence of facial movement in the upper and lower 
face) 
0 Normal 
(extends arems 90 (or 45) degrees for 10 seconds 
without drift) 
1 Drift 
2 Some effort against gravity 
3 No effort against gravity 
4 No movement 
6. Motor Function - Leg (right and O Normal (hold leg 30 degrees position for 5 
left): seconds) 
7. Limb Ataxia 
1 Drift 
2 Some effort against gravity 
3 No effort against gravity 
4 No movement 
0 No ataxia 
1 Present in one limb 
2 Present in two limbs 
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NIHSS continued 
8. Sensory O Normal 
Appendices 
(Use pinprick to test arems, 1 Mild to moderate decrease in sensation 
legs,trunk and face -- compare side 2 Severe to total sensory loss 
to side) 
9. Best Language O No aphasia 
( describe picture, name items, read 1 Mild to moderate aphasia 
sentences) 2 Severe aphasia 
3 Mute 
10. Dysarthria (read several words) 0 Normal articulation 
11. Extinction and inattention 
1 Mild to moderate slurring of words 
2 Near unintelligible or unable to speak 
9 Intubated or other physical barrier 
0 Normal 
1 Inattention or extinction to bilateral simultaneous 
stimulation 
in one of the sensory modalities 
2 Severe hemi-inattention or hemi-inattention to 
more than one modality 
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Appendix IV: Structured interview for the modified 
Rankin Scale 
Question Score 
Is the patient dead? Yes 6 
No 
Does the patient require constant Yes 5 care (bedridden)? 
No 
Is assistance essential for basic AOL Yes 
(eg eating , toilet use, washing, 
transfers and walking)? 
No 
Is assistance essential for instrumental Yes 
AOL (eg cooking, handle finances, 
house chores and travel l ing? 
No 
Are there any l imitations in usual social Yes 
activities (eg return to work, looking after 
others), but patient is AOL independent? 
No 
Does the patient experience any symptom Yes 
due to the stroke (eg difficulty speaking , 
numbness, visual problems, paresis)? 
No 
0 




U heeft, als het goed is, bijna mijn proefschrift uitgelezen en in dit laatste 
deel wil ik benadrukken dat velen hebben bijgedragen aan het tot stand 
komen van dit proefschrift. Ik zou daarom iedereen die mij geholpen 
heeft, willen bedanken voor zijn of haar inzet. Een aantal personen zou 
ik in het bijzonder willen noemen. 
Allereerst wil ik mijn promotor, prof. dr. J .H.A. De Keyser 
bedanken. Beste Jacques, de afgelopen jaren waren voor mij zeer 
leerzaam en het is voor mij een grate eer om onder uw begeleiding 
onderzoek te mogen verrichten. Uw enthousiasme en optimisme zijn 
bijzonder motiverend en ik heb bewondering voor de manier waarop u 
manuscripten reviseerde ( en clan ook op zeer korte termijn!). Daarnaast 
ben ik u dankbaar dat u tijd voor dit onderzoek heeft vrijgemaakt tijdens 
mijn klinische opleiding tot neuroloog. Ik hoop dat dit 
promotieonderzoek de basis vormt voor verdere wetenschappelijke 
samenwerking. 
Copromotor dr G.J.R. Luijckx, beste Gert-Jan. Het was onder 
andere jouw idee om de resultaten van trombolyse bij het acute 
herseninfarct in het UMCG te evalueren, wat uiteindelijk een belangrijk 
deel van dit proefschrift vormt. Jij weet als geen ander klinische 
vraagstukken helder geformuleerd te krijgen, wat aanknopingspunten 
biedt voor verder onderzoek. Hartelijk dank voor de intensieve 
begeleiding en ik hoop in de toekomst nog veel van je te mogen leren. 
Copromotor dr P.C.A.J. Vroomen, beste Patrick. Ik ben je 
erkentelijk voor al je adviezen en commentaar op de hoofdstukken. 
Tevens waren de uitgebreide discussies leerzaam en gaven ook nieuwe 
inzichten in het onderzoek. Bedankt. 
De leescommissie, prof. dr. L.J. Kappelle, prof. dr. M. Limburg en 
prof dr. F. Zijlstra, dank ik voor hun bereidheid het manuscript te 
beoordelen. 
Beste Roy Stewart, jij bent van onmis bare waarde geweest qua 
begeleiding van de statistiek en methodologie. Ik heb in een aantal jaren 
ontzettend veel van je geleerd op dit terrein, waarvoor mijn dank. 
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Friedus van der Minne, bedankt voor je assistentie om de 
trombolyse database 'up to date' te houden. Coby Bolwijn, jouw 
bereidheid om de Rankin scores te bepalen bij de patienten die 
getrombolyseerd zijn heh ik bijzonder gewaardeerd. 
Het personeel van verpleegafdeling K2V A: de dagelijkse praktijk van 
de trombolyse in het UMCG wordt mede door jullie mogelijk gemaakt. 
Het is goed om te zien dat jullie zo'n enthousiast team zijn! 
De medische staf van de afdeling N eurologie wil ik bedanken voor 
de interesse in mijn promotieonderzoek, de mogelijkheid onderzoek met 
kliniek te combineren en voor de prettige samenwerking (en supervisie). 
Dr. B.M. de Jong, ondanks dat vasculaire neurologie niet primair uw 
aandachtsgebied is, heh ik met u interessante discussies gevoerd onder 
andere over mijn onderzoek, waarvoor dank. 
Aile collega 'aiossen' van de neurologie, bedankt voor de goede 
samenwerking en gezellige sfeer (zowel binnen als buiten het 
ziekenhuis!). Marcus Koch, die zich 2 weken eerder 'doctor' mag 
noemen clan ik. Naast je nuttige bijdragen aan mijn onderzoek, mocht ik 
ook meedenken en participeren in jouw promotieonderzoek over 
progressie bij MS. Samen hebben we een aantal mooie artikelen, 
waaronder enkele in dit proefschrift, geschreven. Karen Koopman, voor 
de discussies op onze onderzoekskamer en voor je bijdrage aan 
hoofdstukken 7 en 8. Succes met de 'sintrom' studie. Rosette Bremmer 
en Katalin Horvath: bedankt voor jullie plezierige begeleiding toen ik 
destijds als onervaren keuze-co onder jullie hoede op K.2V A stage liep. 
J eroen de Vries, Harold Wei ten berg en J op Mostert, voor alle 
humoristische momenten. Else Burgers, voor het grondig doorlezen van 
de samenvatting. 
Het stafsecretariaat van de afdeling neurologie, Tineke Bijzitter, 
Marga Veldthuis, Renee Staal en Yvonne Krautz, bedankt voor jullie 
assistentie (zoals met die lastige faxapparaten). Bernie Duym, voor zijn 
diagnostische (en uiteraard therapautische) vaardigheden, wanneer er 
weer eens een PC was "gecrashed." 
Elisabeth Schrijvers, als student onderzoeker heb je fantastisch werk 
verricht hetgeen voor een belangrijk deel heeft bijgedragen aan 
hoofdstuk 6 en heeft geleid tot 2 publicaties. 
Aile neurologen, werkzaam in de ziekenhuizen random het UMCG: 
Delfzicht ziekenhuis Delfzijl, Wilhelmina ziekenhuis Assen, Refaja 
ziekenhuis Stadskanaal, Martini ziekenhuis Groningen, St-Lucas 
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ziekenhuis Winschoten; dank voor de intensieve samenwerking om de 
huidige infrastructuur random trombolyse in de regio mogelijk te maken. 
Olav van der Jagt, bedankt voor je rol als paranimf. Hoewel de 
tennisbanen praktisch in je achtertuin staan, is het al weer enige tijd 
geleden dat we een balletje hebben geslagen; het wordt weer eens tijd . . .  
Succes met je promotieonderzoek bij de orthopedie in Rotterdam. 
Zwany Metting, ook bedankt voor je rol als paranimf. Ik wens je 
succes met jouw promotieonderzoek (ik blijf het jammer vinden dat ik 
geen proefpersoon in je onderzoek kon (mocht?) zijn . . .  ). 
Mijn familie en vrienden, bedankt voor jullie interesse en alle 
gezellige momenten, die erg welkom waren. 
Mijn ouders kan ik niet genoeg bedanken. Jullie hebben mij van 
kinds af aan volop de ruimte gegeven voor mijn persoonlijke 
ontwikkeling en mij de mogelijkheid gegeven om te studeren. Door de 
jaren heen zijn jullie altijd vol belangstelling geweest. Ik heb 
bewondering voor hoe jullie de draad weer oppakken na papa's CV A. 
J oost en Anne, het is fijn om jullie als oudere broer en zus te 
hebben. Jullie zijn altijd bereid om mij bij te staan, wanneer dit nodig is. 
J oost bedankt voor je tips voor de lay-out van dit proefschrift. Anne 
bedankt voor het grondig doorlezen van het proefschift. Michie! de 
Boer, voor je snelle en bruikbare antwoorden per email of telefoon 
wanneer ik om je advies vroeg over statistiek of epidemiologie. Koen en 
Meg, bedankt voor jullie luisterend oor tijdens het ontspannen in 
Frankrijk. 
Lisa, al ruim 11 jaar zijn we samen. J ouw lief de en steun zijn van 
onschatbare waarde en ik hoop van harte samen met je oud te warden! 
Sofie, mijn kleine meid, je maakt me zeer gelukkig en samen met Lisa, 
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